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Transporters are cell membrane proteins, which mediate the cellular influx or efflux of 
compounds. Transporters expressed in tissues important for pharmacokinetics, can play 
a crucial role in drug absorption, distribution and excretion.  
 
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are 
used to treat hypercholesterolemia and to prevent cardiovascular diseases. Statins are 
usually well-tolerated and most adverse effects are mild. Statin-induced muscle toxicity 
is generally dose- and concentration-dependent. The inhibition of statin transport can alter 
statin plasma concentrations and thus the risk of adverse effects. 
  
The aim of the study was to characterize the transport of atorvastatin, fluvastatin, 
pitavastatin, pravastatin and rosuvastatin via ABC efflux transporters, including breast 
cancer resistance protein (BCRP), P-glycoprotein (P-gp), multidrug resistance-associated 
protein (MRP) 2-4 and 8 in vitro.  
 
Vesicular transport assays were used to investigate statin transport through specific efflux 
transporters. The transport studies were divided into three parts: screening of statin 
transport, time-linearity of transport and concentration-dependent transport. 
 
The results demonstrated that atorvastatin and pitavastatin are substrates of BCRP, P-gp 
and MRP3, fluvastatin is a substrate of BCRP, P-gp, MRP2, MRP3 and MRP4, 
pravastatin is a substrate of MRP3 and rosuvastatin is a substrate of BCRP, P-gp and 
MRP4 in vitro. Simvastatin acid was not transported by any of the studied transporters.  
  
This thesis improves general understanding of pharmacokinetic properties of atorvastatin, 
fluvastatin, pitavastatin, pravastatin and rosuvastatin. These data are useful in predicting 
the effects of transporter-mediated drug-drug interactions and genetic variability in 
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Transporters are membrane proteins, which regulate the passage of endogenous and 
foreign compounds, such as drugs, in the body (Chen et al., 2001; Shin et al., 2017; Suzuki 
et al., 2003). Transporters have a crucial role in drug absorption, distribution, metabolism 
and elimination (ADME), resulting in an effect on drugs pharmacokinetics and 
pharmacodynamics (Benet et al., 1996; Greiner et al., 1999; Kawahara et al., 1999; 
Sparreboom et al., 1997). Alternations in transporter activity caused by other drugs or 
genetic variation can result in changes to drug pharmacokinetics (Keskitalo et al., 2009a; 
Maeda et al., 2006).  
Transporters are divided into two major superfamilies: ATP-binding cassette (ABC) 
superfamily, consisting of 48 members, and solute carrier (SLC) superfamily, consisting 
of 300 members (Dean et al., 2001; Keogh, 2012; Muller, 2006). Both ABC and SLC 
superfamilies can be further subdivided into smaller subfamilies based on similarities in 
structures or sequences, and for example, ABC transporters are categorized into seven 
subfamilies (ABC-A to ABC-G) based on sequence identity (Vasiliou et al., 2009). 
Transporters from both superfamilies have a wide range of substrates including foreign 
compounds, small peptides, bile salts and hormones (Abe et al., 1998; van Edert, 1999; 
Kullak-Ublick et al., 2001). 
ABC transporters vary structurally from each other, but they all share the same base 
structure including two transmembrane domains (TMDs) and two nucleotide-binding 
domains (NBDs) (Higgins and Linton, 2004). TMDs are hydrophobic regions, which vary 
structurally between transporters, and play a major part in substrate recognition and form 
a binding pocket for the substrate. NBDs are conserved proteins, which bind to and 
hydrolyze adenosine triphosphate (ATP), producing energy for membrane protein to 
operate. (Johnson and Chen, 2017) As an example of the structural variety, the number 
of terminal membrane domains can vary with different transporters. Multidrug resistance-
associated proteins (MRP) 1, 2, 3, 6 and 7 have a third membrane-spanning domain, but 
from the same family, MRP4, 5 and 8 do not (Belnsky et al., 1998; Hopper et al, 2001; 
Bera et al., 2001; Tammur et al., 2001; Yabuuchi et al., 2001).  In addition, the structure 
of breast cancer resistance protein (BCRP), which is a so-called half-transporter, is 
composed of only one transmembrane domain and one nucleotide-binding domain (Xu et 
al., 2004). To form a functional BCRP complex, it requires two half-transporter subunits 
to combine into a homodimer (McDevitt et al., 2006; Xu et al., 2004). 
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A transporter’s binding pocket formed by TMDs varies between outward- and inward-
facing conformations based on binding of substrate and ATP, followed by ATP 
hydrolysis, conformational changes and different exposure of binding pocket (Jardetzky, 
1966; Johnson and Chen, 2017). When an ABC-transporter’s binding pocket translocate 
from inward- to outward-facing, substrate affinity decreases and substrate is able to pass 
across the membrane (Ward et al., 2013). The steps, which are included in ABC 
transporters’ cycle (binding of substrate, binding of ATP, NBD dimerization, 
transmembrane domain conformational switch, ATP hydrolysis, releasing the substrate 
in the other side and returning from the cycle ready to the next activation) are known but 
the specific order of these steps is still unclear (Verhalen and Wilkens, 2011; Ward et al., 
2013; Zarrabi et al., 2014). 
The most convincing evidence indicating a role for transporters in drug pharmacokinetics 
in humans comes from pharmacogenetic studies. For example, a decreased function 
single nucleotide variant in the SLCO1B1 gene encoding the organic anion transporting 
polypeptide 1B1 (OATP1B1) influx transporter, is associated with a markedly increased 
systemic exposure to many statins and an increased risk of simvastatin-induced muscle 
toxicity (Pasanen et al., 2006; SEARCH Collaborative Group et al., 2008; Niemi et al., 
2011). Moreover, decreased function variants in the ABCG2 gene encoding the BCRP 
efflux transporter are associated with a markedly increased exposure and enhanced 
cholesterol-lowering efficacy of rosuvastatin (Ghasman et al., 2012; Keskitalo et al., 
2009a). Moreover, transporters have been implicated in several drug-drug interactions. 
For example, the P-glycoprotein (P-gp) -inhibiting antifungal itraconazole has been 
shown to increase the systemic exposure to the oral anticoagulant dabigatran 
(Pureksaritanont et al., 2017).  
1.21 P-glycoprotein 
P-gp efflux transporter was found in 1976 by Juliano and Ling and it is the first discovered 
multidrug resistance protein. P-gp is also known as multidrug resistance protein 1 
(MDR1). P-gp transporter protein is expressed on the apical membrane of small intestinal 
epithelial cells (Drozdzik et al., 2019; Thiebaut et al., 1987), capillary endothelial cells in 
the brain (blood-brain barrier) (Virgintino et al., 2002), hepatocytes in the liver (Ng et al., 
2000), proximal tubule epithelial cells in the kidney (Afrouzian et al., 2018) and in the 
pancreas (Thiebaut et al., 1987) (table 1). The P-gp protein abundance is high in the brain 
microvascular endothelial cells, but protein levels are still lower than those of for example 
BCRP (Shawahna et al., 2011). P-gp can transport a large selection of compounds, but 
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good P-gp substrates are often lipophilic, positively charged and their molecular weight 
is greater than 300 (Sharom et al., 1998; Sharom, 2014). For example, estradiol (Barnes 
et al., 1996) and cortisol (Uedas et al., 1992) are good endogenous substrates for P-gp. In 
addition, P-gp transports multiple drugs, such as dabigatran etexilate (Ishiguro et al., 
2004), digoxin and paclitaxel (Collett et al. 2004). 
1.22 MRP1 
MRP is a second type of transporter discovered in multidrug resistant cancer cells (Cole 
et al., 1992). The first discovered MRP was later named MRP1. The MRP1 protein is 
mainly found in different cancer cells, but it has also been detected for example in the 
placental trophoblast (Nagashige et al., 2003), blood-testis barrier, oral epithelium and 
kidney urinary collecting duct tubules (Wijnholds et al., 1998). MRP1 transports multiple 
different compounds including endogenous substrates such as bilirubin (Jedlitschky et al., 
1997), glutathione conjugates, and glucuronide conjugates (Jedlitschky et al., 1996), and 
exogenous compounds like antivirals (Srinivas et al., 1998).  
1.23 MRP2 
MRP2 was originally named as canalicular multispecific organic anion transporter 
(cMOAT) and it has been studied for several decades. The MRP2 protein is expressed on 
the apical membrane of hepatocyte in the liver (Nies et al., 2001), in the proximal tubules 
of kidney (Schaub et al., 1999), on the apical membrane of epithelial cells in the small 
intestine (Fromm et al., 2000), in the colon (Sandusky et al., 2002), gallbladder (St-pierre 
et al., 2000), bronchi (Sandusky et al., 2002) and placental syncytiotrophoblasts (St-pierre 
et al., 2000) (table 1). MRP2 is therefore expressed throughout the human body. Harwood 
et al (2019) have concluded that the MRP2 protein is most abundant in jejunum and 
second abundant in ileum when compared with MRP3, BCRP and P-gp. In the liver, the 
abundance of MRP2 is similar to P-gp, but compared with BCRP, it is five times more 
abundant and around twice as abundant as MRP3, while OATP1B1 and OATP1B3 are 
approximately ten times more abundant than MRP2 (Burt et al 2016). MRP2 can transport 
a broad range of compounds and it shares many substrates with MRP1. MRP2 substrates 
include, for example, bilirubin glucuronide, glutathione and sulfate conjugates 
(Jedlitschky et al., 1996, 1997). Because of its ability to transport a wide range of 
compounds and its expression in pharmacokinetically important tissues, MRP2 appears 
to play an important role in the elimination of bile acids, conjugated drug metabolites and 




MRP3 has a similar selection of substrates as MRP1 and MRP2, and it is able to transport 
monoanionic bile acids, (Soroka et al., 2001), and glucuronide (Bodó et al., 2003) and 
glutathione conjugates (Zeng et al., 2000). The MRP3 protein is expressed on the 
basolateral membrane of epithelial cells in the intestine (Li et al., 2019), in the cortex of 
adrenal gland (Scheffer et al., 2002), in the liver (Nies et al., 2001), kidney (Li et al., 
2019), pancreas and gallbladder (König et al., 2005) (table 1). In addition, MRP3 mRNA 
is expressed in lower levels in the lung, bladder, spleen, stomach and tonsils (Kool et al., 
1997). The abundance of MRP3 transporter protein is highest in the adrenal glands and 
in the kidney, but in the liver the protein expression levels are typically low (Scheffer et 
al., 2002). Still, mRNA levels are usually reported to be high in the liver (Kool et al., 
1997). The protein abundance in the jejunum is lower than that of MRP2 but almost 
double when compared to BCRP and in the colon MRP3 is significantly more abundant 
than P-gp, BCRP, MRP2 or MRP4 (Harwood et al., 2019). MRP3 expression can be 
induced in different circumstances (Aleksunes et al., 2008; Le Vée et al., 2019). 
1.25 MRP4 
In contrast to MRP3, MRP4 mRNA levels are reported to be minor in the liver (Knauer 
et al., 2010). Highest MRP4 mRNA levels occur in the kidney and small intestine, and 
lower expression occurs in the skeletal muscle (Knauer et al., 2010). MRP4 protein is 
expressed on the basolateral membrane of hepatocytes (Rius et al., 2003), apical 
membrane of proximal tubules of kidney (Van Aubel et al., 2002), in the intestine, brain 
(Nies et al., 2004), erythrocytes (Klokouzast et al., 2003), platelets  (Jedlitschky et al., 
2004), pancreas (König et al., 2005) and adrenal gland (Zelcer et al., 2003) (table 1). 
Drozdzik et al (2019) have recently studied protein abundance of transporters in the 
human liver and intestine, finding that in the colon the protein abundance of MRP4 is 
very similar to MRP2 and almost double compared to P-gp or BCRP, but lower than 
MRP3. In the duodenum, the relative abundance of MRP4 is comparable to the colon, but 
in the rest of the small intestine, the proportion of MRP4 of all efflux transporters is 
diminished to about half. In the study of Drozdzik et al (2019), MRP4 protein was not 
detected at all in the liver. MRP4 transports bile acids, like MRP2 and MRP3, and other 
substrates which include compounds such as dehydroepiandrosterone-3-sulfate (Zelcer et 
al., 2003), and conjugated steroid hormones (Chen et al., 2001). Like other transporters, 
the substrate specificity of MRP4 consists of a wide variety of compounds, but the actual 
method how it can recognize, bind and transport both hydrophobic and hydrophilic 




The ABCC11 gene encoding for MRP8 and the mRNA were first identified by Bera et al 
(2001), who also found that it is highly expressed at the mRNA level in breast cancer. 
Since then, MRP8 protein is found in the gut (Matsumoto et al., 2014), liver (Magdy et 
al., 2013), testis (Klein et al., 2014) and brain (Bortfeld et al., 2006) (table 1). MRP8 
mRNA is also found in the prostate and placenta (Bera et al., 2001). MRP8 shares similar 
substrate specificity with MRP4 and is able to transports nucleotide analogs, lipophilic 
anions and monoanionic bile acids (König et al., 2013). Like MRP4, MRP8 does not have 
N-terminal membrane domain, which separates these two transporters from MRP2 and 
MRP3 (Guo et al., 2003). A genetic variant in the ABCC11 gene determines whether the 
earwax is dry or wet (Yoshiura et al., 2006). 
1.27 BCRP 
BCRP was originally found in 1998 from breast cancer cells by Doyle et al (1998).  The 
origin breast cancer cells gave the transporter also its name. BCRP protein is located on 
the apical membrane of epithelium of the small intestine and colon, on the canalicular 
membrane of hepatocytes, in the placental syncytiotrophoblasts, mammary glands (ducts 
and lobules of breast) (Maliepaard et al., 2001), on the apical membrane of proximal 
tubule cells in kidney (Huls et al., 2008), and in the endothelial cells of blood-brain barrier 
(Cooray et al., 2002) (table 1). BCRP mRNA is expressed in lower amount in the prostate, 
testis and in the skeletal muscle (Doyle et al., 1998; Knauer et al., 2010). Like P-gp, the 
protein abundance of BCRP is high in the microvessels, with slightly higher amounts than 
P-gp (Uchida et al., 2011). BCRP protein is quite evenly distributed along the small 
intestine, in a manner similar to MRP2 (Harwood et al., 2019). BCRP is known to 
transport antibiotics, antivirals, calcium channel blockers (Shin et al., 2017), 
mitoxantrone (Özvegy et al., 2001), sulfasalazine (Jani et al., 2009) and topotecan (Li H 
et al., 2008). Its endogenous substrates include dehydroepiandrosterone sulfate (Suzuki 







Table 1. Localizations of selected ABC transporters in human tissues. 
Transporter Gene Localization 
P-gp ABCB1 Liver, kidney, gut, brain and pancreas 
MRP2 ABCC2 Liver, kidney, gut, gallbladder, bronchi and placenta 
MRP3 ABCC3 Liver, kidney, gut, pancreas, gallbladder and adrenals 
glands 
MRP4 ABCC4 Liver, kidney, gut, brain, pancreas, blood cells and adrenal 
glands 
MRP8 ABCC11 Liver, testis, gut and brain 
BCRP ABCG2 Liver, kidney, gut, brain, placenta and mammary glands.   
 
1.3 Statins 
Cardiovascular diseases are among the most common causes of death globally (Roth et 
al., 2015; Wilkins et al., 2017). Atherosclerosis is a major factor causing coronary heart 
disease and stroke, and the risk of developing atherosclerosis is directly linked with 
increased total serum cholesterol (Bonora et al., 2003; Kannel et al., 1964; The Lipid 
Research Clinics Coronary Primary Prevention Trial results, 1984). High plasma low-
density lipoprotein (LDL) cholesterol concentration is associated with endothelial 
dysfunction, inflammation, foam cell formation and unstable plaques, which are 
underlying causes of LDL’s role in atherosclerosis  (Ehara et al., 2001; Grosheva et al., 
2009; Kinlay et al., 2001; Mohty et al., 2008; Reddy et al., 1994; Singh et al., 2017). 
Development of atherosclerosis is a sum of multiple factors, including LDL, but also 
interplay between metabolic and inflammatory processes (Graham et al., 2017; Lubos et 
al., 2007; Yuan et al., 2001). 
Cholesterol is synthesized in the liver via a pathway also known as the “mevalonate 
pathway”. In this synthesis, the rate limiting step is when HMG-CoA is transformed to 
mevalonate by HMG-CoA-reductase (Goldstein and Brown, 1990). When this critical 
step is inhibited, LDL receptors are upregulated in the liver, LDL is cleared from blood 
circulation and the total and LDL cholesterol concentrations in the blood are decreased 
(Parini et al., 2008).  
Statins are HMG-CoA reductase inhibiting drugs that are used to treat 
hypercholesterolemia and to prevent cardiovascular diseases (Sacks et al., 1996; 
Scandinavian Simvastatin Survival Study Group, 1994). Statins have been shown to 
reduce morbidity and mortality associated with cardiovascular diseases and the effect is 
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shown for patients with and without coronary heart disease (Cholesterol Treatment 
Trialists, 2012; Horwich et al., 2004). In addition to decreasing cholesterol levels, statins 
also decrease triglyceride levels (Jones P et al., 2003). The statins’ mechanism of action 
is competitive and reversible, which means statin medication is usually lifelong (Endo et 
al., 1976).  
Statins have been suggested to have additional beneficial effects independent of the lipid-
lowering mechanism. These are called pleiotropic effects. Pleiotropic features are most 
likely a consequence of reduction of systemic inflammation, endothelial dysfunction, and 
platelet hyper-reactivity (Anderson et al., 1995; Bickel et al., 2002; Huhle et al., 1999; 
Treasure et al., 1995). These effects include, for example, reduced concentration of 
thrombotic factors (for example D-dimer) (Kaba et al., 2004) improvement of endothelial 
function (Treasure et al., 1995), modification of inflammatory reactions (Patti et al., 
2006), antioxidant effects (Wassmann et al., 2001) antithrombotic effects, prevention of 
platelet aggregation (Ali et al., 2009) and stabilization of plaques (Sato et al., 2010). Even 
though pleiotropic effects are recognized, their mechanisms are still mostly unclear. It has 
been suggested that pleiotropic effects involve endothelial-derived nitric oxide (NO) 
(Laufs and Liao, 1998).  Hypercholesterolemia causes poor bioactivity and impaired 
formation of endothelial-derived NO (Tamai et al., 1997; Tanner et al., 1991). 
Endothelial-leukocyte interactions (Jädert et al., 2012), vascular smooth muscle 
proliferation (Janssens et al., 1998), vasodilation (Vallance et al., 1989), and platelet 
aggregation (Radomski et al., 1987), all of these are dependent of endothelial NO. Statins 
increase endothelial NO synthase and by that endothelial NO level, which could be a 
mediator of pleiotropic effects (Laufs and Liao, 1998).  
Statins are strongly associated with a lower risk of Alzheimer disease (Haag et al., 2009), 
but also with improvement of other conditions, such as dementia (Jick et al., 2000) and 
chronic obstructive pulmonary disease (COPD) (Soyseth et al., 2006). COPD is usually 
a progressive disease where the airflow is chronically limited and COPD patients in many 
cases develop ischemic heart disease (IHD) (de Lucas-Ramos et al., 2012). Statins have 
been demonstrated to improve prognosis after acute coronary events and to decrease the 
mortality rate of COPD patients (Cannon et al., 2004; Soyseth et al., 2006).   
Statins are usually well-tolerated drugs and most adverse events are mild (Bellosta et al., 
2004). Common mild adverse events are abdominal pain (Siedlik et al., 1999), headache 
(Jones P et al., 2003), nausea (Cilla et al., 1996), and rare adverse events include, myalgia, 
myopathy (Pasternak et al., 2002) and insomnia (Tuccori et al., 2008). Myopathy is a 
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condition whose symptoms are skeletal muscle pain or weakness and increased creatine 
kinase levels (Tobert, 1988). In the worst case, myopathy develops into life-threatening 
rhabdomyolysis (Joy and Hegele, 2009). Rhabdomyolysis is condition where skeletal 
muscles have severe injuries and lysis, resulting in the release of muscle components into 
the circulation (Armitage, 2007). In rhabdomyolysis creatine kinase levels are 
approximately 40 times greater than the upper limit of normal, while in myopathy this 
level is up to ten times greater (Armitage, 2007; Silva et al., 2007). Rhabdomyolysis can 
also lead to acute renal failure, which may be fatal (Grossman et al., 1974).  
In addition to adverse events, statins have been associated with increased risk of other 
conditions, such as type 2 diabetes (Sattar et al., 2010). This association with diabetes has 
noted in some cases to depend on the dose and potency of statin (Dormuth et al., 2014). 
The mechanism is not well understood, but a few explanations have been suggested. 
Statins (for example atorvastatin) can cause reduced expression of insulin sensitive 
glucose transporter type 4 (GLUT4), which transports glucose into the cells (Jiang et al., 
2016). Since GLUT4 plays a crucial role in glucose metabolism, its disturbance might 
have severe outcomes. Sarcopenia is also one of the adverse effect of statins, which is 
more common in elderly patients, and includes progressive loss of skeletal muscle mass 
and weaker muscle function (Delmonico et al., 2007; Goodpaster et al., 2006; 
Herghelegiu et al., 2018). This is important in the case of diabetes, because sarcopenia 
can cause insulin resistance and contribute to the development of diabetes (Srikanthan et 
al., 2010). Statins have multiple ways to increase risk for diabetes and statins’ unfavorable 
effect to mitochondrial function and dysfunction in skeletal muscle (Jones S et al., 2003), 
adipose tissue (Abe et al., 2008) and pancreatic beta cell (Xia et al., 2008) has been 
studied. These are associated with insulin resistance and so with diabetes (Stienstra et al., 
2014).    
Cholesterol is not the only product of mevalonate pathway (Parker et al., 1984). When 
statins inhibit the mevalonate pathway, the synthesis of other compounds may also be 
diminished. By this mechanism, statins inhibit the synthesis of isoprenoid intermediates 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) (Laufs and 
Liao, 1998). These compounds play a role for example in post-translational modifications 
of Ras and Rho (Adamson et al., 2003). This is notable, because Ras and Rho are involved 
in regulating cell proliferation, differentiation, apoptosis, and cytoskeletal changes (Chen 
et al., 1996; Haudek et al., 2009; Machesky et al., 1997; Mulcahy et al., 1985). 
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All statins share the same mechanism of action, but they differ markedly in 
pharmacokinetic properties. These differing properties may lead to interindividual 
differences in the cholesterol-lowering efficacy and risk of adverse effects of individual 
statins. Pharmacokinetic properties of atorvastatin, fluvastatin, pitavastatin, pravastatin, 
rosuvastatin and simvastatin acid are summarized in the table 2.  
1.31 Atorvastatin 
Atorvastatin is currently one of the most commonly used statins (Li S et al., 2019). It is a 
synthetic drug, which is orally administered as a calcium salt of the active acid form (Cilla 
et al., 1996). Approximately 40% of the oral dose is absorbed from the gut (Black et al., 
1998). Solubility of atorvastatin is high at the natural intestinal pH of 6 (Kearney et al., 
1993). Atorvastatin undergoes major first-pass metabolism and partly as a result its oral 
bioavailability is around 14% (Amidon et al., 2014; Lennernäs, 2003). Atorvastatin binds 
strongly to plasma proteins, by more than 90 (Gibson et al., 1997). In the intestine, 
(requires low pH) or through an enzymatic acyl glucuronide intermediate pathway or 
coenzyme A intermediate pathway (Kearney et al., 1993; Li et al., 2006; Prueksaritanont 
et al., 2002). Atorvastatin is mainly metabolized by CYP3A4. Both atorvastatin and 
atorvastatin lactone are substrates for this metabolizing enzyme, but atorvastatin lactone 
has significantly higher affinity for CYP3A4. Atorvastatin lactone is also more lipophilic 
than the acid form. In addition to CYP3A4, also CYP2C8 is able to metabolize 
atorvastatin, but only at a low rate. (Jacobsen et al., 2000) Atorvastatin acid and 2-
hydroxyatorvastatin acid actively inhibit HMG-CoA reductase, contributing to the 
efficacy of the drug (Lea and McTavish, 1997). 2-hydroxyatorvastatin and 4-
hydroxyatorvastatin can be lactonized via formation of acyl glucuronide intermediates 
(Goosen et al., 2007). Reversely, lactones can be hydrolyzed back to acid forms 
spontaneously or by esterases and paraoxonases (Billecke et al., 2000; Vickers et al., 
1990a). A major route for the elimination of atorvastatin is through biliary excretion and 
more than 98% of atorvastatin is eliminated via feces (Lennernäs, 2003). The remaining 
dose (less than 2%) is excreted into the urine (Stern et al., 1997). The half-life of 
atorvastatin is 14 hours (Kantola et al., 1998). The active HMG-CoA reductase inhibitory 
effect may be longer due to longer half-lives of active atorvastatin metabolites (Lins et 





Fluvastatin was the first fully synthetic statin. Like most of the statins, it is orally 
administered in the active acid form. Fluvastatin is water soluble compound, which is 
rapidly and nearly completely (90-98%) absorbed from the small intestine (Tse et al., 
1992). Plasma protein binding of fluvastatin is very high (over 99%) (Tse et al., 1993). 
Fluvastatin, like atorvastatin and simvastatin, undergoes significant first-pass 
metabolism, which results in a bioavailability of around 30% (Tse et al., 1992). Like most 
other statins, fluvastatin is almost completely metabolized (Dain et al., 1993). Fluvastatin 
has six metabolic pathways which include hydroxylation, loss of the 1-isopopyl group, 
beta-oxidation, lactone formation, threo-isomer formation and conjugation (Dain et al., 
1993). The primary metabolizing enzyme for fluvastatin is CYP2C9, which is highly 
expressed in the gut and liver (De Waziers et al., 1990; Läpple et al., 2003). The three 
main metabolites are 5-hydroxy-fluvastatin, 6-hydroxy-fluvastatin and N-desisopropyl-
fluvastatin (Fischer et al., 1999). 6-hydroxy-fluvastatin and N-desisopropyl-fluvastatin 
are formed by CYP2C9, while the formation of 5-hydroxy-fluvastatin is also catalyzed 
by CYP3A4, CYP2C8 and CYP2D6 (Fischer et al., 1999). Around 60% of an oral dose 
of fluvastatin is converted into these three main metabolites (Scripture and Pieper, 2001). 
Even though 5- ja 6-hydroxy-fluvastatin inhibit HMG-CoA reductase by about 88% and 
45% of the effect of parent fluvastatin, their contribution to the cholesterol-lowering 
efficacy of fluvastatin is insignificant due to their low concentrations (Dain et al., 1993). 
Approximately 90% of an oral dose of fluvastatin is excreted into the bile and feces, and 
around 5% into the urine. In addition, all the three metabolites are detected in the feces. 
Fluvastatin has a very short half-life compared to other statins, only 0.5-1h. (Tse et al., 
1992) 
1.33 Pitavastatin 
Pitavastatin differs from other statins by its structure. It has a synthetic cyclopropyl side 
group, which gives pitavastatin some unique features (Suzuki et al., 2001). One clear 
difference of pitavastatin is its ability to decrease cholesterol synthesis with lower doses 
compared to other statins (Budinski et al., 2009; Ose et al., 2009). It has been estimated 
to be about 7 times more potent HMG-CoA inhibitor than pravastatin (Aoki et al., 1997). 
Pitavastatin is administered orally in the active acid from and its absorption occurs mainly 
in the upper gastrointestinal tract. The absorption of pitavastatin is rapid and extensive, 
approximately 80%. Like other statins, pitavastatin binds highly to plasma proteins, by 
more than 96%. (Fujino et al., 1999a) Binding occurs mostly with albumin and alpha 1-
acid glycoprotein (Fujino et al., 1999b). The oral bioavailability of pitavastatin is greater 
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than 60% (Fujino et al., 1999a), which is relatively high compared to other statins. 
Pitavastatin undergoes only limited metabolism and is mainly metabolized by 
glucuronidation to form pitavastatinlactone, but some oxidative metabolism also occurs 
via CYP2C9 and CYP2C8 (Fujino et al., 2003; 2004). Because of the cyclopropyl moiety, 
CYP3A4 cannot metabolize pitavastatin (Suzuki et al., 2001). As a result of minor 
metabolism, pitavastatin is mostly excreted into the bile in the unchanged form (Kajinami 
et al., 2000). Clearance of pitavastatin into the bile is rapid, but the half-life is relatively 
long due to enterohepatic circulation. Enterohepatic circulation can enhance the oral 
bioavailability and extend the duration of action of pitavastatin. (Kajinami et al., 2006) 
The final excretion occurs mainly through feces and less than 5% is excreted in the urine 
(Catapano, 2010). The half-life of pitavastatin is about 14 hours (Fujino et al., 1999b).  
1.34 Pravastatin 
Pravastatin was originally derived from fungi and it is one of the most hydrophilic statins 
(Serizawa et al., 1991). Pravastatin is orally given, and its main absorption site is upper 
part of small intestine (Triscari et al., 1995). Only 34% of orally give pravastatin is 
absorbed and this has been suggested to be one of the main reasons why its oral 
bioavailability is 18% (table 2) (Singhvi et al., 1990). Pravastatin binds to plasma proteins 
considerably less than other statins, its plasma protein binding is between 43% and 54% 
(Pan et al., 1993; Singhvi et al., 1990). Between 30% and 50% of pravastatin is 
metabolized and its metabolites are 3′α-isopravastatin, 3′α,5′β-dihydroxy-pravastatin, 
desacyl-dehydropravastatin, 3′′-hydroxy-pravastatin and 6′-epipravastatin (Hatanaka, 
2000). 3’alpha-isopravastatin isomer is the main pravastatin metabolite (Jacobsen et al., 
1999). Both 3′α-isopravastatin and 6′-epipravastatin can be formed in the stomach even 
before absorption by nonenzymatic acid-catalyzed isomerization and even 25% of 
pravastatin can be biotransformed in the stomach (Everett et al., 1991; Triscari et al., 
1995). 3′α-isopravastatin has a low inhibitory effect towards HMG-CoA reductase and 
this does not significantly contribute to the overall LDL-cholesterol-lowering efficacy of 
pravastatin (Everett et al., 1991; Pan et al., 1990). CYP3A4 is the main metabolizing 
enzyme for converting pravastatin into 3’’-hydroxy pravastatin, but CYP-dependent 
metabolism is not as significant for pravastatin’s metabolism as it is for some other statins 
(Everett et al., 1991; Jacobsen et al., 1999). Pravastatin is mostly excreted into the feces, 
approximately 70%, but it also has a relatively high urinary excretion, 20% of oral dose. 
The peak plasma concentration of pravastatin is reached in approximately 1 hour and its 




Like atorvastatin and fluvastatin, also rosuvastatin is a synthetic statin. Rosuvastatin is 
relatively hydrophilic (Rosenson, 2003). The oral bioavailability of rosuvastatin has been 
estimated to be 20% and its hepatic extraction ratio is 0.63 (Martin et al., 2003a). The 
peak plasma concentration of rosuvastatin is reached in 3 to 5 hours (Cooper et al., 2002). 
Rosuvastatin is 88% bound to plasma protein (Tomlinson and Hu, 2013). Rosuvastatin is 
excreted mainly into bile, 90% of a dose is found in feces, and around 77% of that in 
unchanged form. The remaining 10 % is excreted into urine. The high proportion of 
unchanged drug in the excreta indicates that metabolism is only a minor route of 
elimination for rosuvastatin (Martin et al., 2003b). The metabolic pathways of 
rosuvastatin include CYP2C9-mediated N-demethylation and uridine diphosphate-
glucuronosyltransferase 1A1- and uridine diphosphate-glucuronosyltransferase 1A3-
mediated acyl-glucuronidation followed by spontaneous lactonization (Marin et al., 
2003b; Prueksaritanont et al., 2002).  The elimination half-life of rosuvastatin is about 20 
hours (Martin et al., 2003b).  
1.36 Simvastatin 
Simvastatin is a fungal-derived statin like pravastatin. Unlike other statins, simvastatin is 
a prodrug administered as the inactive simvastatin lactone.  Simvastatin lactone is 
converted into the active simvastatin acid in the plasma, liver and intestinal mucosa 
(Tubic-Grozdanis et al., 2008). Conversion from lactone to acid can occur spontaneously 
or via enzyme-catalyzed hydrolysis mediated by carboxylesterases (Vickers et al., 
1990b). Simvastatin lactone and acid are mainly metabolized by CYP3A4, but a minor 
part is also metabolized by CYP3A5 (Prueksaritanont et al., 2003). The acid form can be 
converted back to lactone via CoASH-dependent pathway or acyl glucuronide 
intermediate (Prueksaritanont et al., 2001, 2002). Simvastatin acid has three main 
oxidative metabolites, which are 6´-hydroxy, 6´-hydroxymethyl, and 6´-exomethylene 
(Vickers et al., 1990b). Simvastatin is well-absorbed from gastrointestinal track (60%) 
(Cheng et al., 1994) and undergoes major first-pass metabolism, occurring in the 
intestinal wall and in the liver (Kato, 2008). The oral bioavailability of simvastatin is low 
(less than 5%) (Tubic-Grozdanis et al., 2008). Plasma protein binding of simvastatin is 
high (98%) (Vickers et al., 1990b). Its half-life is around 2 hours (Mousa et al., 2000), 
and 60% of the oral dose is excreted into feces and 13% into urine (Todd and Goa, 1990). 
Simvastatin lactone is highly and simvastatin acid relatively lipophilic. Its lipophilicity is 
suspected to be the reason why it is challenging to demonstrate simvastatin acid transport 
in vitro, for example for OATP1B1 (Sharma et al., 2012), even though simvastatin acid 
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is a highly sensitive OATP1B1 substrate in vivo (Pasanen et al. 2006, SEARCH 
Collaborative Group et al.,2008). 
 
Table 2. Summary of the pharmacokinetic parameters of statins. Adapted from “Drug 
interactions with lipid-lowering drugs: mechanisms and clinical relevance” by 
Neuvonen, P. J., Niemi, M., and Backman, J.T., 2006, Clin Pharmacol Ther, 80(6):565-
81. Copyright (2006) by the American Society for Clinical Pharmacology and 
Therapeutics 
 Atorvastatin Fluvastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin 
Absorption 
(%) 
30 98 80 35 50 60-85 
Bioavailability 
(%) 
12 29 60 18 20 < 5 
Hepatic 
extraction (%) 
70 >70 70 45 63 >80 
Protein 
binding (%) 
>98 >98 96 50 90 >95 
Elimination 
half-life (h) 




CYP3A4 CYP2C9 - CYP3A4 CYP2C9 CYP3A4 
 
1.4 Statins as substrates for transporters 
Transporters play a major part in transporting statins across biological membranes. It is 
important to study which drugs are substrates for each transporter, since these have an 
influence on drugs’ ADME and safety features. With this information, unnecessary drug-
drug interactions could be avoided and drugs prescribed more individually. Statins’ 
passage through efflux transporters have been studied. BCRP and MRP2 have been 
shown to transport atorvastatin (Lee et al., 2019; Shin et al., 2017), fluvastatin (Lin et al., 
2011), pravastatin (Afrouzian et al., 2018) and rosuvastatin (Lee et al., 2019; Knauer et 
al., 2010). In addition, BCRP transports pitavastatin (Vildhede et al., 2016). MRP3 is 
demonstrated to transport pitavastatin (Vildhede et al., 2016) and rosuvastatin (Kanda et 
al., 2018), while MRP4 and P-gp are shown to transport atorvastatin (Hochman et al., 
2004; Knauer et al., 2010;), pitavastatin (Kanda et al., 2011; Vildhede et al., 2016), 
pravastatin (Afrouzian et al., 2018) and rosuvastatin (Kanda et al., 2018; Knauer et al., 
2010). Simvastatin acid is a difficult compound to study in vitro and there are only a few 
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reports considering simvastatin and efflux transporters. Simvastatin lactone is shown not 
to be a substrate of BCRP, MRP2 nor P-gp in vitro (Keskitalo et al., 2009b; Li et al., 
2011). In addition, statins’ uptake via OATP influx transporters have been investigated. 
OATP1B1 and OATP1B3 are strongly associated to transport atorvastatin (Koenen et al., 
2012; Nakakariya et al., 2016), fluvastatin (Kopplow et al., 2005), pitavastatin (Hirano et 
al., 2006), pravastatin (Hsiang et al., 1999; Seithel et al., 2007)) and rosuvastatin (Ho et 
al., 2006). The orientation of transporters and direction of statin transport are presented 
in figure 1. 
 
Figure 1. Orientation of selected ABC efflux transporters in the liver and intestine. Figure 
created with BioRender.com. 
 
1.5 Methods for studying drug transporters 
Several cell-based and membrane-based methods are available for investigating the role 
of transporters in drug pharmacokinetics in vitro. Moreover, animal models and human 
pharmacogenetic and drug-drug interaction studies can be employed to investigate their 
roles in vivo. 
Membrane-based assay system is based on vesicles, which includes transporters on their 
membrane.  When studying ABC efflux transporters, commonly used vesicles are inside-
out orientated (Keppler et al., 1998). To produce these membrane vesicles, multiple cell 
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lines expressing the transporter of interest can be used, for example baculovirus-infected 
insect cells or transfected mammalian cells (Brand et al., 2011; Gu et al., 1996). Vesicles 
are a good method in mechanic studies, since the interest is in direct interaction of the 
drug with the transporter protein. The advantage is that the drug of interest has direct 
access to the transporter and effluxed drug accumulates inside the vesicles (Giacomini, 
2010). These properties make membrane vesicle transport assay suitable for transporter 
kinetic studies and for QSAR analyses (Saito et al., 2006). The weakness is that it might 
not work for lipophilic compounds, since they are able to pass the membrane by diffusion 
in or out of the vesicle, or may bind to the membrane (Krumpochova et al., 2012). 
Vesicle-based assays are also suitable for investigating transporter inhibition (Saito et al., 
2006). 
Whole cell-based assays are useful methods, for example, when investigating the 
transport of lipophilic compounds, vectorial transport across polarized cells or 
transporter-enzyme interactions (Desmarais et al., 2009; Wensaas et al., 2007). Cell-
based methods are good for perceiving the bigger picture, because they include 
membranes, original orientation and a number of endogenous of transporters and other 
cellular mechanisms. The common deficiencies for cell-based methods are that primary 
cells, e.g., hepatocytes, may lose endogenous expression of transporters over time and, 
on the other hand, immortalized cells might not sufficiently mimic the endogenous 
metabolic and transport profiles of primary cells (Giacomini, 2010).  
Cell based assays are divided roughly into these four methods:  
1) Polarized cell lines without recombinant transporters are frequently used 
methods to investigate transport across important biological membranes, such as 
the small intestinal wall and the blood-brain barrier (Chabane et al., 2009; 
Madgula et al., 2007). In this method, the transcellular passage of a substrate can 
be determined in both directions, apical-to-basolateral and vice versa. Several cell 
lines can be used, for example Madin-Darby canine kidney (MDCK) cells and 
Caco-2 cells (Chabane et al., 2009; Madgula et al., 2007; Zhang et al., 2004), but 
they all share similar limitations. For example these cell lines have low 
permeability for hydrophilic compounds, transporter composition differs from 
endogenous pool of transporters (Hilgendorf et al., 2000), and transporter 
expression can vary between laboratories (Hayeshi et al., 2008). 
2) In single- and double-transfected cell lines, single or multiple transporters can 
be expressed at the same time. MDCK and human embryonic kidney 293 
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(HEK293) cells are often used in this method. These cell lines are oriented as a 
monolayer and are suitable for influx, efflux and kinetics measurements, 
especially for influx kinetics (Kameyama et al., 2005; Shin et al., 2017). To 
determine the quantitative transport of the drug, cell lines can express both, influx 
and efflux transporters or only one of those categories (Zhang et al., 2009). Even 
though the cells can be double-transfected, the model seldom sufficiently imitates 
in vivo situation (Bartholomé et al., 2007).  
3) Primary cells are obtained from intact tissue and due to the origin from living 
tissue, these cell lines express all the endogenous features of origin. However, 
primary cells easily adapt to culture conditions and lose their endogenous 
properties. This phenomenon can be controlled to some extent with suitable 
culture conditions. For transport experiments, it is important to maintain cell 
polarization, and the expression and localization of transporters. Primary cells are 
used for determining drug intrinsic clearance, transport, metabolism, toxicity, 
disposition, and drug interactions. (Klein et al., 2015; Pichard et al., 1990; Raab 
et al., 2011; Thomas et al., 2004)  
4) Sandwich-cultured primary hepatocytes are a suitable method to maintain 
primary hepatocyte polarity. Sandwich-cultured primary hepatocytes have been 
demonstrated to imitate endogenous function of hepatic influx transporters 
(Marion et al., 2007). As mentioned in primary cells, hepatocytes lose their 
polarity easily. However, when primary hepatocytes are cultured between two 
gelled collagen layers, cell polarity is possible to regenerate (LeCluyse et al., 
1994; Liu et al., 1999). Sandwich-cultured primary hepatocytes also have some 
limitations. Limitations of this model include decreased activity of cytochrome 
P450 enzymes and that the method is laborious (Boess et al., 2003). 
In vivo transporter studies include studies with transporter-knockout or humanized animal 
models, inhibition and imaging studies (Feng et al., 2008; Learned-Coughlin et al., 2003; 
Polli et al., 2009). Knockout models have several limitations, since strain, sex, diet and 
housing can cause variation in transporter expression (Chu et al., 2006; Giacomini, 2010; 
Merino et al., 2005; More and Slitt, 2011; Vlaming et al., 2006). Different species have 
also shown variation in substrate specificities. For example rats express Mrp2 tenfold 
higher compared to human (Li M et al., 2008) and Bcrp is expressed in higher levels in 
the liver in males (Merino et al., 2005).  
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Imaging techniques, such as positron emission tomography and gamma scintigraphy, are 
non-invasive imaging techniques useful to determine the role of transporters in tissue 
distribution. Positron emission tomography can be used for example to determine 
pharmacodynamic endpoints and gamma scintigraphy to study modulation and activity 
of transporters (Senthilkumari et al., 2009; Young et al., 1999). Imaging techniques are 
laborious, which limits their usage. 
Pharmacogenetic studies in humans have proven highly effective in determining the role 
of transporters in drug pharmacokinetics, efficacy, and toxicity in humans (Chasman et 
al. 2012; Keskitalo et al. 2009a; Pasanen et al. 2006; SEARCH Collaborative Group et 
al., 2008). This is a useful strategy only when sufficiently common functionally 
significant genetic variability exists in the transporter of interest. Drug-drug interaction 
studies also provide useful information on the role of transporters in drug 
pharmacokinetics in humans, but this approach is impeded by the lack of specific 
transporter inhibitors and substrates (Lehtisalo et al. 2020), 
1.6 Aim of the study 
In this thesis, the focus is on six ABC-type efflux transporters: BCRP, MRP2, MRP3, 
MRP4 and MRP8 and P-gp and six statins: atorvastatin, fluvastatin, pitavastatin, 
pravastatin, rosuvastatin and simvastatin acid. These transporters were chose based on 
their expression in tissues important for pharmacokinetics, possible involvement in drug-
drug interactions and genetic variants. Other transporters are associated with statins but 
MRP8 was included based on its novelty. Lovastatin was not included in the study, since 
it is relatively old statin and is rarely used in Finland (Kela, 2019). On the other hand, 
pitavastatin which is not used in Finland was still included, since pitavastatin is relatively 
new, potent and interesting statin (Budinski et al., 2009; Ose et al., 2009). 
The aim is to characterize which of the statins are substrates of these transporters and to 
determine the respective transport kinetic parameters by using vesicular transport assay. 
The goal is to establish better understanding of statin pharmacokinetics and statin-
transporter interactions. The ultimate goals are to provide reliable data that is useful in 
systems pharmacology modelling of statins, increase understanding of statin 






In this thesis, the vesicular transport assay was used to study the accumulation of six 
statins inside the vesicles with six efflux transporters. The study was divided into three 
main phases: screening of statin transport, determination of time-dependent transport and 
determination of concentration-dependent transport. Screening provided first indication 
which statins are substrate of each transporter. If ratio of transport in the presence and 
absence of ATP was two or more, statin was considered as substrate. Transporters, which 
showed statin transport or were associated with the statin in question in the literature, 
were selected into second phase of the study. The time-dependent transport of statins 
determined optimal reaction time for the third phase. The third and final phase of the 
study determined concentration-dependent transport of the statins and pharmacokinetic 
parameters of the active transport for each statin.  
2.1 Optimization:  
The vesicular transport assay was first optimized to confirm the quality of the results and 
reproducibility. Optimization included several experiments where pre-wetting the filters 
before sample transfer, terminating the reaction with washing buffer, evaporating the 
samples and dissolving into organic solvent, reduction of the elution volume, elution two 
times and adding vesicles into external standard were examined.  
In the optimization, pre-wetting the filters with MQ-water was evaluated. Results showed 
that pre-wetting the filter before transferring the samples into filters decreased the 
apparent statin transport in the presence and absence of ATP compared to dry filters 
(figure 2 and table 3). Variation between replicates seemed to be lower when filters were 
pre-wetted. Reaction termination was tested with washing buffer to evaluate possible 
effect of commercial stopping buffer to mass spectrometric measurements. The results 
revealed apparent lower statin transport when using washing buffer to reaction 
termination compared to stopping buffer (figure 2 and table 3). Surprisingly, pravastatin 
was transported in MRP3-expressing vesicles more in absence than presence of ATP in 
pre-wetted filters when reaction was terminated with stopping buffer. The impact of pre-
washing to external standard was also studied by treating filter plate in two different ways 
before adding standard solutions: dry filters and filters treated three times with stopping 
buffer and twice with washing buffer. This filter treatment did not affect the results (figure 
3 and table 3). 
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The effect of samples evaporation was investigated during optimization. Samples were 
evaporated after experiment and dissolved into acetonitrile aiming to concentrate the 
samples. Results showed that evaporation did not improve reproducibility. Conversely 
signals included even larger variation and measured transport values were vague (figure 
4 and table 4). Pravastatin’s ATP-dependent transport via MRP3 and variation was more 
consistent without evaporation. 
To evaluate appropriate elution volume, the same protocol was used with pitavastatin, 
pravastatin, rosuvastatin, and 5(6)-Carboxy-2′,7′-dichlorofluorescein (CDCF). Elution 
volume experiment performed with CDCF showed increased fluorescence with 
increasing elution volume in the presence of ATP, but in the absence of ATP MRP2 did 
not transport CDCF (figure 5 and table 5). Experiment performed with statins revealed 
that decreasing elution volume from 100µl to 50µl increased transported statin 
concentration to a small extent only, without increasing variety between replicates (figure 
6 and table 6). Also, eluting samples two times proved that all the statin is eluted at the 
first time and second elution is not necessary (figure 7 and table 7). Pravastatin 
accumulation is higher in absence of ATP in twice eluted 200µl, but variation in the 
results was notable. The experiment was performed by adding a second eluant after first 
elution and results were compared to the experiment where pravastatin was eluted only 
once.  
Vesicles were added into external standard to evaluate vesicles’ possible statin or internal 
standard binding. Results showed that vesicles did not affect results, which indicated that 




























Figure 2. Pre-wetting the filters with 
MQ-water before transferring samples 
into filters and terminating reaction with 
two different buffers. Pravastatin 
accumulation in MRP3 was studied with 
pre-wetted and dry filters. Reaction was 
terminated by using ice cold washing 
buffer and commercial stopping buffer, 
to detect possible effect of proteins in 
stopping buffer on mass spectrometric 
measurements. 
 
Figure 3. Effect of pre-washing filters before 
adding external standard. Experiment is the 
same as in figure 1, but the results were 
adjusted with two different standards. 
Second standard filter was pre-washed three 
times with stopping buffer and twice with 
washing buffer before adding external 
standard on the filters. 
 
Figure 4. Evaporating samples and 
dissolving into organic solvent. Effect of 
evaporating and dissolving accumulated 
statin in acetonitrile was studied with 
10µl pravastatin and MRP3. 
 
Figure 5. Evaluation of the effect of elution 
volume on CDCF fluorescence. The elution 
volume was studied first with fluorescent 
substrate CDCF and MRP2. CDCF 
accumulation was studied with three 






















Table 3. Results of optimizing pre-wetting of filters and reaction termination buffer 
experiments. The mean and SD of statin accumulation in the presence and absence of 
ATP, ATP-dependent transport and ratio between ATP + and ATP – for 200µM 
pravastatin and MRP3 in different experimental conditions. Wetting of filters with MQ-
water before transferring samples into filters and terminating reaction with two different 
buffers. Reaction was terminated by using ice cold washing buffer and commercial 
stopping buffer, to detect possible effect of proteins in stopping buffer on mass 
spectrometric measurements. Results were determined by using two external standards. 
Filters of second external standards (std 2) were washed three times with stopping buffer 














ATP + / 
ATP - SD
Pre-Wetting + Washing buffer 35.56 2.02 23.82 4.10 11.73 4.57 1.49 0.27
Pre-Wetting + Washing buffer (std 2) 35.02 2.02 23.42 4.10 11.60 4.57 1.50 0.28
Dry + Washing buffer 106.22 16.65 51.33 31.33 54.89 35.48 2.07 1.30
Dry + Washing buffer (std 2) 104.84 16.50 50.58 31.03 54.27 35.14 2.07 1.31
Pre-Wetting + Stopping buffer 77.56 25.60 26.49 7.62 -51.07 26.71 0.34 0.15
Pre-Wetting + Stopping buffer (std 2) 76.49 25.25 26.04 7.54 50.44 26.35 2.94 1.29
Dry + Stopping buffer 244.22 114.47 133.33 1.33 110.89 114.48 1.83 0.86
Dry + Stopping buffer (std 2) 241.02 113.18 131.87 1.54 109.16 113.19 1.83 0.86
Figure 6. Evaluation of the effect of 
elution volume on pitavastatin, 
pravastatin and rosuvastatin 
transport. Statins were studied with 
two elution volumes 100µl and 50µl. 
Pitavastatin was accumulated in 
BCRP, pravastatin in MRP3 and 
rosuvastatin in P-gp. 
 
Figure 7. Double elution and vesicles effect 
on external standard. Samples were eluted 
twice to confirm all the accumulated statin 
is eluted. Vesicles were added to external 
standard to evaluate vesicles possible effect 
on results. Experiment was performed with 
two concentrations 200µM and 150µM 






Table 4. Evaporation studies. The mean and SD of statin accumulation in presence and 
absence of ATP, ATP-dependent transport and ratio between ATP + and ATP – for 10µM 




Table 5. The impact of elution volume on CDCF transport. The mean and SD of statin 
accumulation in the presence and absence of ATP and ratio between ATP + and ATP – 
















ATP + / 
ATP - SD
BCRP 2.25 0.03 1.10 0.22 1.15 0.23 2.04 0.45
BCRP evaporation 2.00 0.50 2.39 0.19 -0.39 0.54 0.84 0.22
MRP2 1.77 0.22 1.02 0.57 0.75 0.61 1.73 0.99
MRP2 evaporation 2.56 0.11 0.93 0.18 1.63 0.21 2.74 0.54
MRP3 4.19 0.02 2.29 1.73 1.90 1.73 1.83 3.12
MRP3 evaporation 3.43 0.62 2.14 0.12 1.29 0.63 1.60 0.30
MRP4 2.81 0.98 1.21 0.18 1.60 1.00 2.33 1.05
MRP4 evaporation 1.67 0.32 4.49 2.87 -2.82 2.88 0.37 0.25
MRP8 1.80 0.59 1.36 0.69 0.44 0.91 1.32 1.07
MRP8 evaporation 1.41 0.13 1.86 0.62 -0.45 0.64 0.76 0.26
P-gp 1.64 0.07 0.98 0.39 0.66 0.40 1.67 0.65
P-gp evaporation 3.08 1.30 2.08 0.50 1.00 1.39 1.48 0.72
Control 1.31 0.29 1.02 0.30 0.30 0.42 1.29 0.48









ATP + / 
ATP - SD
100µl 2474.33 102.77 36.67 3.21 67.48 6.55
75µl 1773.33 337.92 34.67 3.21 51.15 10.84
50µl 894.33 43.62 30.67 1.53 29.16 2.03
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Table 6. Results of elution volume experiments. The mean and SD of 10µM statin 
accumulation in presence and absence of ATP, ATP-dependent transport and ratio 
between ATP + and ATP – in two different elution volume.  
 
 
Table 7. Results of double elution and vesicles effect on standard experiments. The mean 
and SD of statin accumulation in the presence and absence of ATP, ATP-dependent 
transport and ratio between ATP + and ATP – for pravastatin and MRP3. Results were 
determined with two external standards. Second standard included the same vesicles 





The screening experiments were performed with two statin concentrations: 1µM and 
10µM. In 10µM experiments, statin accumulation was more detectable and deviation was 
smaller compared to 1µM experiments. In addition, at 1 µM, the quantities of some statins 
were below limit of quantification. Based on these reasons, 10µM experiment results were 
used to evaluate which statins are substrates of which transporters (figure 8 and table 8).  
The mean and SD of statin transport in presence and absence of ATP, ATP-dependent 
transport and ratio between ATP + and ATP – for all the statins and transporters are 
summarized in the table 8. 
BCRP, MRP3 and P-gp showed effective transport of atorvastatin (ratios of 1.6, 2.22 and 














ATP + / 
ATP - SD
Pitavastatin 100µl BCRP 13.31 1.41 2.73 0.17 10.58 1.42 80.01 9.78
Pitavastatin 50µl BCRP 16.55 0.48 2.44 0.12 14.12 0.50 134.01 7.84
Pravastatin 100µl MRP3 6.64 1.64 2.06 0.47 4.57 1.70 14.21 4.76
Pravastatin 50µl MRP3 7.31 0.90 2.48 0.55 4.83 1.05 13.29 3.37
Rosuvastatin 100µl P-gp 3.40 0.06 2.15 0.61 1.24 0.62 5.54 1.58













ATP + / 
ATP - SD
200µM 134.67 38.18 68.53 41.74 132.27 113.13 1.96 1.32
150µM 96.51 50.21 85.67 18.10 21.69 106.73 1.13 0.63
200µM eluted twice 162.71 54.79 162.00 49.97 1.42 148.31 1.00 0.46
150µM eluted twice 109.29 46.27 79.78 54.52 59.02 143.00 1.37 1.10
200µM (vesicles in the standard) 258.67 72.82 131.38 79.95 127.29 108.14 1.97 1.32
150µM (vesicles in the standard) 185.29 96.44 164.22 34.67 21.07 102.48 1.13 0.63
200µM eluted twice (vesicles in the standard) 311.82 104.69 378.76 135.87 -66.93 171.52 0.82 0.40
150µM eluted twice (vesicles in the standard) 209.42 88.76 153.07 104.44 56.36 137.06 1.37 1.10
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ATP-dependent transport of atorvastatin by MRP8 (1.3 pmol/min/mg) was slightly higher 
compared to control vesicles (1.2 pmol/min/mg), but the transport ratio (1.2) was lower 
than in control (1.3). Fluvastatin screening was performed with two isomers: 3R, 5S-
fluvastatin and 3S, 5R-fluvastatin. Both isomers were very good substrates of BCRP 
(ratios of 3.8 and 3.1), MRP3 (ratios of 2.1 and 3.2), MRP4 (ratios of 2.3 and 4.08) and 
P-gp (ratios of 2.8 and 2.4). MRP8 showed ATP-dependent transport of both fluvastatin 
isomers, with greater transport of 3S,5R-fluvastatin (4.8 vs. 2.8 pmol/min/mg). However, 
the uptake ratio of 3R,5S-fluvastatin was at the same level with control (1.3). MRP2 did 
not transport either of the fluvastatin isomers (ratios of 1.3 and 1.4).  
BCRP transported pitavastatin over two-fold compared to control vesicles (ratios of 4.6 
and 1.7) and also P-gp showed good transport (ratios of 3.3). MRP8 and MRP3 
transported pitavastatin to a minor extent only (ratios of 1.8 and 2.4). MRP2 nor MRP4 
did not transport pitavastatin (ratios of 1.4 and 1.5). 
Large variability existed in the transport experiments with pravastatin. BCRP was the 
only transporter which clearly transported pravastatin (ratio of 2.0). MRP3 and MRP4 
appeared to transport pravastatin, even though there was large variability between 
replicates (ratios of 1.8 and 2.33). Transport of pravastatin by MRP2, MRP8 and P-gp 
was very weak and only slightly higher than control (0.8, 0.4, 0.7 and 0.3 pmol/min/mg). 
Rosuvastatin was highly transported by BCRP (ratio of 8.4). MRP4 and MRP8 showed 
also good rosuvastatin transport (ratios of 2.6 and 5.0), but rosuvastatin transport by 
MRP8 showed large variation. Rosuvastatin did not accumulate in MRP2 or MRP3 
vesicles as compared with control (ratios of 1.0, 1.3 and 1.5). P-gp showed only modest 
transport of rosuvastatin (ratio of 2.0). Large variation was observed in the transport 
experiments with simvastatin acid and significant accumulation of simvastatin acid was 
observed in the absence of ATP. P-gp showed ATP-dependent transport of simvastatin 







Figure 8. Screening of 10µM atorvastatin, 3R,5S-fluvastatin, 3R,5S-fluvastatin, 
pitavastatin, pravastatin, rosuvastatin and simvastatin in BCRP, MRP2, MRP3, 
MRP4, MRP8, P-gp and control vesicles. 
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Table 8. Summary of screening results. The mean and SD of statin accumulation in the 
presence and absence of ATP, ATP-dependent transport and ratio between ATP + and 

















ATP + / 
ATP - SD
10µM Atorvastatin BCRP 10.32 0.66 6.42 1.24 3.90 1.41 1.61 0.33
MRP2 7.61 0.45 5.04 0.46 2.57 0.64 1.51 0.16
MRP3 12.28 1.35 5.53 1.30 6.75 1.87 2.22 0.58
MRP4 6.45 1.23 4.64 0.53 1.81 1.34 1.39 0.31
MRP8 7.56 0.39 6.30 0.41 1.26 0.57 1.20 0.10
P-gp 12.48 1.75 4.07 0.57 8.41 1.84 3.06 0.60
Control 5.22 1.04 4.03 0.24 1.19 1.07 1.30 0.27
10µM 3R,5S-Fluvastatin BCRP 21.84 2.41 5.75 1.21 16.09 2.70 3.80 0.91
MRP2 8.21 0.27 6.46 2.58 1.75 2.59 1.27 0.51
MRP3 11.08 0.44 5.24 1.43 5.84 1.49 2.12 0.58
MRP4 8.58 0.75 3.68 0.25 4.90 0.79 2.33 0.26
MRP8 10.83 0.50 8.01 1.05 2.82 1.16 1.35 0.19
P-gp 12.16 0.13 4.28 0.50 7.89 0.52 2.84 0.34
Control 7.16 0.26 5.47 1.34 1.70 1.36 1.31 0.32
10µM 3S,5R-Fluvastatin BCRP 16.68 5.21 5.40 2.13 11.28 5.63 3.09 2.16
MRP2 3.99 0.93 2.81 2.08 1.18 2.28 1.42 0.79
MRP3 8.91 2.31 2.81 0.51 6.10 2.37 3.17 0.72
MRP4 8.50 1.05 2.08 0.43 6.42 1.14 4.08 0.53
MRP8 8.14 3.14 3.34 0.75 4.80 3.22 2.44 0.93
P-gp 8.45 1.52 3.58 0.99 4.87 1.82 2.36 0.72
Control 4.67 2.06 3.89 0.80 0.78 2.21 1.20 0.58
10µM Pitavastatin BCRP 9.93 1.24 2.17 0.14 7.76 1.25 4.57 0.64
MRP2 2.61 0.34 1.86 0.06 0.75 0.35 1.40 0.19
MRP3 3.44 0.24 1.42 0.31 2.02 0.40 2.43 0.56
MRP4 3.06 0.39 2.08 0.65 0.98 0.76 1.47 0.50
MRP8 4.54 1.17 2.54 0.31 2.00 1.21 1.79 0.51
P-gp 5.79 0.61 1.78 0.52 4.01 0.80 3.25 1.01
Control 3.67 1.10 2.11 0.22 1.56 1.12 1.74 0.55
10µM Pravastatin BCRP 2.25 0.03 1.10 0.22 1.15 0.23 2.04 0.45
MRP2 1.77 0.22 1.02 0.57 0.75 0.61 1.73 0.99
MRP3 4.19 0.02 2.29 1.73 1.90 1.73 1.83 3.12
MRP4 2.81 0.98 1.21 0.18 1.60 1.00 2.33 1.05
MRP8 1.80 0.59 1.36 0.69 0.44 0.91 1.32 1.07
P-gp 1.64 0.07 0.98 0.39 0.66 0.40 1.67 0.65
Control 1.31 0.29 1.02 0.30 0.30 0.42 1.29 0.48
10µM Rosuvastatin BCRP 23.19 2.93 2.78 0.95 20.42 3.08 8.35 3.05
MRP2 1.80 0.23 1.84 0.49 -0.05 0.55 0.97 0.29
MRP3 2.88 0.66 2.29 0.24 0.59 0.71 1.26 0.32
MRP4 5.53 3.72 2.14 0.49 3.39 3.75 2.59 1.84
MRP8 10.71 9.00 2.15 0.42 8.56 9.01 4.99 4.31
P-gp 3.65 0.78 1.79 0.29 1.87 0.83 2.04 0.55
Control 3.07 0.24 2.09 0.41 0.98 0.48 1.47 0.31
10µM Simvastatin BCRP 3.96 0.65 4.45 1.54 -0.49 1.67 0.89 0.34
MRP2 2.59 0.06 4.78 2.04 -2.19 2.04 0.54 0.23
MRP3 3.50 0.14 4.85 2.41 -1.35 2.42 0.72 0.36
MRP4 2.88 0.25 4.54 1.59 -1.66 1.61 0.63 0.23
MRP8 3.65 0.19 3.19 0.09 0.47 0.21 1.15 0.07
P-gp 4.15 0.87 2.19 0.23 1.96 0.91 1.89 0.45
Control 3.38 0.78 2.07 0.06 1.31 0.78 1.64 0.38
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2.3 Time-dependent transport  
Transporter-statin pairs showing transport in the screening experiments were selected into 
time-dependent transport experiments (table 9). In addition, transporters that did not show 
any signs of ATP-dependent transport or were not differed from the control vesicles, but 
transport statins according to the literature, were selected. Since simvastatin acid did not 
show significant transport, it was not included in the further experiments. 
Time-dependent transport of each statin was studied with three time points: 5, 10 and 15 
min. The overall trend was (with some exceptions), that when the incubation time was 
increased, statin transport increased also in the control vesicles. In this case, longer 
incubation time did not increase ATP-dependent transport. Transport may not be linear 
anymore at the time point of 5 min, which could not be seen since 5 min was the first time 
point. The 5 min incubation time was selected for the concentration-dependent transport 
experiments, because good statin accumulation was observed in this time and 5 min was 
practical. Mean and SD of ATP-dependent transport and ratio in three time points are 
summarized in the table 10. 
Atorvastatin time-dependent transport was studied with BCRP, MRP2, MRP3, MRP4 and 
P-gp (figure 9). These results confirmed earlier findings indicating that atorvastatin is a 
substrate of BCRP, MRP3 and P-gp (ratios over 2.0 in all three time points). MRP2 and 
MRP4 weak transport in both the screening and time-dependent transport, and were not 
included in the concentration-dependent transport experiments. Atorvastatin 
accumulation in the control vesicles was low and very similar in all the time points (ratios 




Figure 9. Time-dependent transport of atorvastatin in BCRP, MRP2, MRP3, MRP4 and 
P-gp vesicles. 
 
Time-dependent transport of 3R, 5S-fluvastatin was studied with BCRP, MRP2, MRP3, 
MRP4, MRP8 and P-gp (figure 10). Control vesicles showed low ATP-dependent 
transport of 3R,5S-fluvastatin, and increased slightly along with an increasing incubation 
time (ratios of 1.1, 1.2 and 1.8). BCRP showed highest 3R,5S-fluvastatin transport of the 
transporters, confirming screening results (ratios around 4 in all time points). MRP3 and 
P-gp indicated also good transport (ratio of 3.1 and 3.0 at 5 min). MRP2, MRP4 and 
MRP8 also transported 3R,5S-fluvastatin, but at a lower rate. 3R,5S-fluvastatin 
accumulation in MRP8 vesicles was similar to control in the two last time points (ratios 




Figure 10. Time-dependent transport of 3R, 5S-fluvastatin in BCRP, MRP2, MRP3, 
MRP4, MRP8 and P-gp vesicles. 
 
3S,5R-fluvastatin time-dependent transport was investigated with BCRP, MRP2, MRP3, 
MRP4, MRP8 and P-gp vesicles (figure 11). 3S,5R-fluvastatin seemed to be a good 
substrate of BCRP, MRP3 and P-gp, as shown in screening experiments results (ratios of 
4.4, 3.1 and 2.7 at 5 min). Transport of 3S,5R-fluvastatin in MRP2 vesicles was lower 
than in the control vesicles (ratios of 1.0 and 1.3 at 5 min), indicating that 3S,5R-
fluvastatin is not substrate of MRP2. MRP4 and MRP8 showed some transport of 3S,5R-





Figure 11. Time-dependent transport of 3S, 5R-fluvastatin in BCRP, MRP2, MRP3, 
MRP4, MRP8 and P-gp vesicles. 
 
Time-dependent transport of pitavastatin was studied with BCRP, MRP2, MRP3, MRP4 
and P-gp vesicles (figure 12). Results showed that pitavastatin transport into the vesicles 
was highest by BCRP (ratios of 5.2, 5.7 and 5.1). This confirmed the screening results. 
MRP3 showed only minor transport of pitavastatin (ratios of 1.9, 1.9 and 1.7). MRP2 and 
MRP8 did not transport pitavastatin more than the control vesicles, which also confirmed 
the screening results (ratios of 1.6, 1.2 and 1.2 at 5 min). In P-gp vesicles, pitavastatin 
transport in time points 5 and 10 min was almost two-fold compared to control vesicles 
(ratios of 3.6 and 1.2 at 5 min), which indicated pitavastatin possibly being a substrate for 





Figure 12. Time-dependent transport of pitavastatin in BCRP, MRP2, MRP3, MRP4 and 
P-gp vesicles. 
 
Time-dependent transport of pravastatin was studied with BCRP, MRP2, MRP3 and 
MRP4 vesicles (figure 13). Significant variation was observed in the pravastatin 
experiments. MRP3 showed accumulation of pravastatin in all three time points, even 
though some variation was observed (ratios of 2.2, 1.5 and 1.7). MRP3 transported 
pravastatin to the highest extent of the investigated transporters. Experiments with BCRP 
vesicles showed high variation, but indicated some transport of pravastatin (ratio of 1.6 
at 5 min).  MRP2 and MRP4 did not show signs of pravastatin transport (ratios of 1.0 and 
1.0 at 5 min). The transport of pravastatin in control vesicles was very low (ratios of 0.8, 




Figure 13. Time-dependent transport of pravastatin in BCRP, MRP2, MRP3 and MRP4 
vesicles. 
 
Time-dependent transport of rosuvastatin was investigated with BCRP, MRP2, MRP4 
and P-gp vesicles (figure 14). As expected based on the screening experiments, 
rosuvastatin was a good substrate of BCRP (ratio of 18.5, 15.5 and 11.0). MRP4 
transported rosuvastatin two-fold compared to the control (ratios of 2.0 and 1.0). 
Transport of rosuvastatin was poor at the 5 min time point (ratio of 1.1) in P-gp vesicles 
but indicated accumulation in 10 and 15 min time points (ratios of 1.9 and 2.0). MRP2 
did not show signs of transport (ratios of 1.1, 1.3 and 1.3).  
 





Table 9. Transporters selected from the screening experiments to the time-dependet 
transport experiments. MRP2 did not show transport of fluvastatin (both isomers), 
pitavastatin, pravastatin or rosuvastatin in the screening, but was selected to be 
investigated based on the literature.  
 BCRP MRP2 MRP3 MRP4 MRP8 P-gp 
Atorvastatin X X X X  X 
Fluvastatin 
(both isomers) 
X X X X X X 
Pitavastatin X X X  X X 
Pravastatin X X X X   
Rosuvastatin X X  X X X 
Simvastatin       
 
Table 10. Summary of time-dependent transport results. Mean and SD of ATP-dependent 









ATP - at 
5min SD
ATP-dependent 





ATP - at 10 
min SD
ATP-dependent 





ATP - at 15 
min SD
Atorvastatin BCRP 196.59 54.50 2.53 0.43 121.09 31.70 2.70 0.58 154.30 38.42 2.31 0.57
MRP2 66.67 19.07 1.61 0.21 90.70 13.26 2.09 0.27 69.30 25.41 1.75 0.41
MRP3 143.20 15.75 2.16 0.23 131.83 16.10 2.57 0.21 160.63 74.25 2.22 0.74
MRP4 43.76 5.83 1.49 0.09 53.38 3.82 1.75 0.08 54.18 9.83 1.71 0.15
P-gp 186.72 33.98 2.46 0.36 108.68 51.98 3.12 1.03 243.93 40.00 3.41 0.66
Control 31.94 13.17 1.22 0.11 27.05 12.22 1.27 0.13 47.81 4.97 1.42 0.05
3R,5S-Fluvastatin BCRP 344.89 92.83 4.05 0.85 419.53 41.64 4.48 0.78 416.61 56.74 4.05 0.84
MRP2 84.79 9.50 2.33 0.17 118.92 10.78 2.60 0.25 100.56 12.72 2.52 0.29
MRP3 177.58 39.73 3.06 0.63 408.84 158.13 4.59 1.49 206.42 34.85 3.72 0.46
MRP4 91.16 22.13 2.50 0.47 195.18 27.30 2.76 0.30 37.86 11.63 2.23 0.68
MRP8 136.75 11.31 2.03 0.12 10.81 8.55 1.36 0.30 41.59 12.11 1.73 0.26
P-gp 195.07 23.71 2.96 0.32 204.26 10.54 2.78 0.12 205.66 35.41 3.54 0.89
Control 4.27 4.81 1.14 0.17 12.42 25.00 1.23 0.46 54.12 19.29 1.83 0.44
3S,5R-Fluvastatin BCRP 310.16 8.85 4.42 0.29 409.59 41.49 4.49 0.48 344.35 51.60 4.25 0.65
MRP2 0.11 13.22 1.00 0.25 79.82 10.24 2.79 0.31 70.75 4.14 2.50 0.12
MRP3 128.54 25.62 3.07 0.75 157.27 26.81 3.47 0.50 179.84 14.52 4.19 0.43
MRP4 49.58 9.54 2.16 0.45 99.10 67.90 3.56 6.18 65.57 47.26 1.89 1.18
MRP8 48.28 14.63 1.71 0.25 86.03 10.38 2.04 0.13 96.89 19.86 1.93 0.27
P-gp 124.87 18.58 2.74 0.33 182.22 12.80 3.08 0.32 182.87 55.35 2.52 0.72
Control 22.36 19.56 1.27 0.27 14.39 3.09 1.62 0.15 69.45 15.89 1.98 0.44
Pitavastatin BCRP 357.56 17.96 5.24 0.58 348.81 58.47 5.71 0.80 281.17 18.38 5.14 0.39
MRP2 38.81 67.72 1.63 1.34 20.66 26.56 1.74 1.00 37.96 25.16 1.71 0.48
MRP3 68.22 26.79 1.92 0.46 78.87 40.53 1.91 0.50 58.31 38.11 1.68 0.75
MRP8 16.66 26.97 1.16 0.28 51.77 14.93 1.68 0.23 -31.74 92.08 0.79 0.48
P-gp 100.11 15.45 3.63 1.12 114.52 3.80 376.65 61.38 12.81 7.30 1.64 0.53
Control 8.84 25.63 1.20 0.59 49.34 17.85 2.41 0.94 -0.48 13.79 0.99 0.41
Pravastatin BCRP 18.43 19.19 1.56 0.78 8.92 29.59 1.22 0.89 13.98 20.61 1.38 0.72
MRP2 1.99 13.86 1.04 0.26 8.58 27.04 1.18 0.58 15.91 5.64 1.68 0.34
MRP3 39.46 15.45 2.24 0.53 18.31 28.36 1.51 0.81 24.99 10.13 1.72 0.47
MRP4 0.64 10.99 1.02 0.30 7.39 9.96 1.25 0.42 19.58 28.65 1.75 1.31
Control -5.11 8.90 0.84 0.28 0.64 15.63 1.02 0.55 -3.78 35.25 0.91 0.82
Rosuvastatin BCRP 343.11 41.39 18.49 2.76 238.86 17.26 15.46 4.08 304.67 30.74 11.03 1.81
MRP2 1.62 2.11 1.06 0.07 5.58 5.70 1.33 0.36 7.02 12.14 1.28 0.50
MRP4 20.74 10.33 1.98 0.66 25.66 4.16 2.84 0.55 22.28 3.53 2.08 0.18
MRP8 4.03 13.18 1.13 0.48 3.88 6.27 1.22 0.40 13.68 11.26 1.65 0.57
P-gp 3.92 4.97 1.14 0.18 21.73 16.56 1.85 1.14 27.43 5.08 2.03 0.19
Control -0.60 6.60 0.97 0.34 2.88 7.50 1.18 0.49 10.65 11.54 1.51 0.58
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2.4 Concentration-dependent transport experiments 
In the concentration-dependent transport experiments each statin was investigated with 
several concentration points, in order to determine kinetic parameters for the statins by 
fitting results into of the Michaelis-Menten equation. All the statins did not reach plateau 
in ATP-dependent transport experiments. Concentration-dependent transport of 
fluvastatin was investigated with racemic fluvastatin. All the pharmacokinetic parameters 
are summarized in the table 11. 
Concentration-dependent transport experiments of atorvastatin confirmed earlier results, 
which indicated that atorvastatin is substrate for BCRP, MRP3 and P-gp (figure 15). 
Increasing transport of atorvastatin with concentration occurred, but a clear plateau of 
ATP-dependent transport was not observed in the BCRP vesicles and only nearly in the 
MRP3 vesicles. In P-gp vesicles, concentration-dependent accumulation reached a 
plateau already after the 25µM concentration point. The Km value of BCRP, MRP3 and 
P-gp seemed to be below 100µM. The Km value of BCRP for atorvastatin  was 82µM, 
that of MRP3 was 33µM and that of P-gp was 11µM. Vmax was estimated to set around 
135 pmol/min/mg in the BCRP, 79 pmol/min/mg in MRP3 and 33 pmol/min/mg in P-gp 
vesicles.  
 
Figure 15. ATP-dependent transport of atorvastatin in BCRP, MRP3 and P-gp vesicles. 
 
Concentration-dependent transport of fluvastatin was investigated with racemic 
fluvastatin for all the transporters (figure 16). BCRP was clearly the best transporter for 
racemic fluvastatin and the concentration-dependent transport curve fitted well with the 
Michaelis-Menten equation. The calculated Vmax and Km values were 340 pmol/min/mg 
and 23 µM for BCRP. MRP2, MRP3, MRP4, MRP8 transported racemic fluvastatin in 
concentration-dependent manner, but plateau of ATP-dependent transport was not 
observed. The calculated Vmax and Km values were 181 pmol/min/mg and 133 µM for 
MRP2. MRP3 was a good transporter for racemic fluvastatin and steady plateau was 
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observed after 100µM. The calculated Vmax and Km for MRP3 were 156 pmol/min/mg 
and 43 µM. Transport by MRP4, MRP8 and P-gp occurred in concentration-dependent 
manner, but clear plateaus were not observed, especially so for P-gp. The estimated Vmax 
and Km values were 54 pmol/min/mg and 33 µM for MRP4, and 85 pmol/min/mg and 62 
µM for MRP8. The estimated Vmax and Km were high for P-gp.  
 
Figure 16. ATP-dependent transport of racemic fluvastatin in MRP2, MRP3, MRP4 and 
P-gp vesicles. 
 
Concentration-dependent transport of pitavastatin was studied with BCRP, MRP3, P-gp 
vesicles (figure 17). BCRP transported pitavastatin at the highest level, but with 
significant variation. MRP3 and P-gp showed minor transport of pitavastatin. Full 
concentration-depend transport and saturation of pitavastatin accumulation was not 
observed for MRP3. Transport by P-gp decrease after 100µM and curve-fitting was not 
complete. The estimated Vmax for BCRP was 94 pmol/min/mg, for MRP3 it was 20 
pmol/min/mg and for P-gp it was 22 pmol/min/mg. Approximated Km values were 15 µM 




Figure 17. Concentration-dependent transport of pitavastatin in BCRP, MRP3, and P-gp 
vesicles. 
Concentration-dependent transport of pravastatin was studied with MRP3 vesicles (figure 
18). MRP3 was the only transporter that showed clear transport of pravastatin in the time-
dependent transport experiment and hence it was the only transporter studied in the 
concentration-dependent experiment. ATP-dependent transport of pravastatin increased 
with concentration, but plateau was not achieved. The Vmax of MRP3-mediated 
pravastatin transport was estimated as 26 pmol/min/mg of protein and Km as 67 µM. 
 
Figure 18. Concentration-dependent transport of pravastatin in MRP3 vesicles. 
 
Concentration-dependent transport of rosuvastatin was studied with three transporters: 
BCRP, MRP4 and P-gp (figure 19). Concentration-dependent transport of BCRP was 
investigated with lower concentration points, which revealed rosuvastatin’s 
concentration-dependent accumulation before saturation. Transport by MRP4 or P-gp 
was much lower compared to BCRP. Transport in MRP4 vesicles at first three 
concentration points (12 µM, 25 µM and 50 µM) increased, but after that variation 
increased and the calculated ATP-dependent transport decreased almost to zero. 
Transport of rosuvastatin by P-gp increased with the concentration, but with significant 
variation in the last three concentration points (100 µM, 150 µM and 200 µM). 
Concentration-dependent transport by P-gp did not fit the Michaels-Menten equation and 
plateau of ATP-dependent transport was not clearly seen. The estimated Vmax for BCRP 
was 87 pmol/min/mg, for MRP4 4 pmol/min/mg and for P-gp 20 pmol/min/mg. The Km 





Figure 19. Concentration-dependent transport of rosuvastatin in BCRP, MRP4 and P-gp 
vesicles. 
 
Table 11. The summary of kinetic parameters of atorvastatin, racemic fluvastatin, 
pitavastatin, pravastatin and rosuvastatin transport in BCRP, MRP2, MRP3, MRP4, 





95% CI of 
Vmax 












P-gp 32.9 28.4 - 38.3 10.7 5.4 - 19.7 1.4 
       
Fluvastatin 
(racemic) 
BCRP 339.8 246.2 - 
535.0 
22.7 5.9 - 80.1 15.8 
 
MRP2 180.6 61.0 - INF 132.7 8.0 - INF 1.9  
MRP3 156.3 68.3 - INF 42.9 0.6 - INF 3.5  
MRP4 54.1 21.9 - INF 32.8 N/A 1.7  




P-gp ~3.8e+015 N/A ~9.9e+015 N/A 0.6 
       
Pitavastatin BCRP 93.8 67.1 - 142.1 14.5 0.1 - 66.5 8.8  




P-gp 22.1 13.6 - 37.4 15.8 -INF - 
91.1 
1.8 
       
Pravastatin BCRP 26.4 9.3 - INF 66.6 N/A 0.2 
       
Rosuvastatin BCRP 87.5 80.6 - 95.1 4.78  3.5 - 6.4 20.4  




P-gp 19.6 9.4 - INF 60.5 2.0 - INF 0.4 
Vmax = maximal velocity, CI = confidence interval, Km = Michaels constant, CL = clearance, INF = 




This thesis evaluated the transport of six clinically used statins by six efflux transporters 
important for drug pharmacokinetics. The results demonstrated significant differences in 
the efflux transport profiles of statins.  
The vesicular transport assay protocol was first optimized with several experiments. The 
aim of the optimization was to ensure the quality and reproducibility of the results. 
Vesicular membrane assay has disadvantages that are mostly related to the lipophilicity 
of the substrate of interest (Gilibili et al., 2017). Lipophilic compounds may diffuse in 
and out of the vesicles, which is why determining their ATP-dependent transport is 
difficult in membrane vesicles. The hydrophilic pravastatin (Log D -0.75) proved to be a 
challenging substrate in the vesicle experiments.  Therefore, optimization experiments 
were mostly carried out with pravastatin.  
According to the manufacturer’s instructions, pre-wetting of the filters on the filter plates 
is not necessary (MultiScreen HTS plate protocol). The impact of pre-wetting was studied 
by adding samples to dry and pre-wetted filters (figure 2). When using dry filters, the 
results showed higher overall transport, but also higher apparent transport in the absence 
of ATP, and more variation. Based on these results, pre-wetted filters were used in the 
subsequent experiments. The impact of stopping buffer on mass spectrometric 
measurements was also investigated. The commercial stopping buffer was delivered with 
the vesicles. To avoid a possible matrix effect on mass spectrometric analysis, the vesicles 
were always washed well with washing buffer to get all the stopping buffer away. The 
stopping buffer was foamy and bubbly, which covered the whole well and formed a film 
over the filter. Bubbles were broken manually with pipet tips so that the washing buffer 
had better access. Even though the stopping buffer is washed away by using washing 
buffer, it may still affect the subsequent measurement. Therefore, the stopping and 
washing of the reaction was tested with washing buffer only. The results showed lower 
apparent statin transport and indicated that the stopping buffer was a better buffer for 
terminating the reaction than washing buffer (figure 2). The experiment was not 
completely successful since in the pre-wetted filters, when reaction was terminated with 
stopping buffer, pravastatin accumulated in MRP3 vesicles more in the absence than in 
the presence of ATP. Results were not completely unambiguous, and it was decided to 




The level of pravastatin transport was very low and its concentration in the vesicles was 
near the mass spectrometric quantification limit. Therefore, the samples were 
concentrated by evaporating the samples after and diluting them into a smaller volume of 
acetonitrile (figure 4). However, this procedure did not improve statin quantification and 
also increased variation in the measurements. Evaporation was therefore not implemented 
in the assay protocol.  
The elution volume was optimized by investigating statin concentration in the eluant at 
different elution volumes. The first experiment was performed by using the fluorescent 
substrate CDCF and MRP2 (figure 5). The aim was to improve statin concentration in 
eluant by decreasing elution volume. However, the measured fluorescence increased with 
elution volume. In fluorescence measurements it is possible that a higher liquid column 
gives a higher signal (the Beer-Lambert law), which probably happened in this 
experiment. For this reason, elution volume was studied also with three statins 
(pitavastatin, pravastatin and rosuvastatin) each with different transporter (BCRP, MRP3 
and P-gp) (figure 6). Lower elution volume of 50µl did not decrease statin yield or 
increase variation, and it was implemented to the protocol.  
In the optimizing, it was also studied if elution is complete after one elution. The filter 
plate was eluted twice, by adding a second fresh eluant after the first elution, which 
confirmed that all the statin is collected (figure 7). A minor difference between once and 
twice eluted statin concentration was observed, which can be explained by normal 
variation between replicates. 
In the assay filters, the external standard and samples were treated differently. Sample 
filters were pre-wetted, washed with stopping and washing buffer, but external standard 
was added to dry filters without washes. External standard also did not contain any 
vesicles. To rule out bias due to the differing treatment of the samples and external 
standard, the possible effects of vesicles and washes on the external standard were 
investigated. To investigate the effects of different treatment of external standard filters 
on the results, results of double elution were determined by using normal external 
standard and external standard which included vesicles (figure 7), and results of pre-
wetting the filters were determined with external standard added to dry and pre-washed 
filters (washed three times with stopping buffer and twice with washing buffer) (figure 
3). In both of these experiments, different treatment of external standard did not affect the 
results. Therefore, the external standard was decided to be added to dry filters without 
vesicles in the subsequent experiments.  
40 
 
The experiments of this thesis consist of three main phases: screening, time-dependent 
transport and concentration-dependent transport experiments. In the screening, BCRP, 
MRP2, MRP3, MRP4, MRP8 and P-gp were investigated as potential transporters for all 
the statins of interest (atorvastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and 
simvastatin). Screening was performed with two concentrations (1 µM and 10 µM), but 
statin transport was more detectable in 10 µM experiments and deviation was smaller 
compared to 1 µM experiments. In addition, at 1 µM, the quantities of some statins were 
below the limit of quantitation. Therefore, 10 µM experiments results were used to 
evaluate which statins are substrate of each transporter. In the time-dependent studies, the 
optimal reaction incubation time was examined more specifically by using one statin 
concentration and three incubation times of 5, 10 and 15 minutes. The trend was with few 
exceptions that when increasing the incubation time, the statin transport increased also in 
absence of ATP and in the control vesicles. This means that ATP-dependent transport did 
not increase, and time-dependent saturation had already occurred before the 5 min time 
point. The 5 min incubation time was selected for the concentration-dependent 
experiments, because statin transport was clearly observed in this time and 5 min was 
practical. In the concentration-dependent experiments, statin transport was examined with 
several concentration points and with the incubation time selected based on time-linearity 
studies. The aim was to detect concentration-dependent transport of statins and to 
determine the transport kinetic parameters for the statins by fitting the results into a 
Michaelis-Menten equation. All the statins did not reach plateau in ATP-dependent 
transport experiments and did not fit well the Michaelis-Menten equation.  
In the screening and time-dependent transport experiments, control vesicles were an 
important tool to confirm statin transport. Control vesicles were not included in the 
concentration-dependent transport experiments, because difference from control vesicles 
was already demonstrated in the time-dependent transport experiments. Control vesicles 
are prepared form HEK293 cells like other vesicles, but they do not contain any 
transfected transporters. It is possible that control vesicles express endogenous 
transporters which may play a role in statin transport (Ahlin et al., 2009; Reid et al., 2003). 
Most statins were transported slightly better in the presence than absence of ATP in 
control vesicles, which supports the presence of endogenous statin transporters in 
HEK293-cell-derived membrane vesicles. 
Previous studies have shown with different methods that atorvastatin is a substrate of 
BCRP (Lee et al., 2019), MRP2 (Shin et al., 2017), MRP4 (Knauer et al., 2010) and P-gp 
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(Hochman et al., 2004; Shin et al., 2017). Transport of atorvastatin by P-gp has also been 
studied in Caco-2 cells and an apparent Km was calculated as 110µM (Boyd et al., 2000). 
The present results indicate a low Km (11µM) of atorvastatin for P-gp, indicating high 
affinity. The present results cannot be directly compared to the results of Boyd et al (2000) 
since the method is different. BCRP and P-gp are both good transporters for atorvastatin, 
but an interesting note in the results is that P-gp shows better transport than BCRP, which 
is often a superior transporter for many statins. Another interesting finding is MRP3, 
which also transports atorvastatin with relatively good affinity. MRP2 transported 
atorvastatin in the screening and time-dependent transport, but to a small extent only and 
was therefore not included in the concentration dependent experiments.  
The screening and time-dependent transport of fluvastatin was conducted with both 
isomers of fluvastatin (3R,3S-fluvastatin and 3S,5R-fluvastatin). However, 
concentration-dependent transport experiments were performed with racemic fluvastatin, 
because isomers were not at that time any more commercially available to purchase, and 
previous stocks were too diluted. BCRP, MRP3, MRP4 and P-gp were the most promising 
transporters for both isomers in the screening and time-dependent transport studies but 
all the transporters were included in concentration-dependent transport of racemic 
fluvastatin. Fluvastatin has been reported to be a substrate of BCRP, MRP2 (Lin et al., 
2011) and P-gp (Li et al., 2011). In the concentration-dependent experiments, BCRP was 
a very good transporter for racemic fluvastatin and MRP3 also showed clear transport of 
fluvastatin. Other transporters might also transport racemic fluvastatin, but that could not 
be confirmed in these experiments. This is slightly surprising, because in the screening 
and in time-dependent transport experiments, both isomers were found to be potential 
substrates of MRP3, MRP4, MRP8 and P-gp in addition to BCRP. Based on this study, 
further studies are required to determine the enantiospecific transport of fluvastatin 
isomers by efflux transporters. 
BCRP, MRP3, P-gp (Vildhede et al., 2016) and MRP4 (Kanda et al., 2011) have 
previously been shown to transport pitavastatin. Vildhede et al (2016) determined the Km 
and Vmax of pitavastatin by using membrane vesicles. Km was 1 µM, 448 µM and 84 µM 
for BCRP, MRP3, P-gp, respectively, and Vmax was 95, 433 and 2380 pmol/min/mg 
protein. MRP2 or MRP4 were not found to transport pitavastatin. Hirano et al (2005) 
reported values for Km and Vmax of 6 µM and 1106 pmol/min/mg protein with BCRP, also 
using membrane vesicles. In the present study, pitavastatin was found to be a substrate of 
BCRP, MRP3 and P-gp. These results are similar to the results of Vildhede et al (2016). 
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The estimated Km values for BCRP, MRP3 and P-gp were 13, 20 and 20 µM, respectively, 
and Vmax values 118, 24 and 35 pmol/min/mg. Both the Km and Vmax values were much 
lower than those reported by Vildhede et al (2016) results. The difference in parameter 
values could be a consequence of variation between measurements or difference in vesicle 
quality and protein expression levels.  
Afrouzian et al (2018) have shown with membrane vesicles that pravastatin is substrate 
of BCRP, MRP2, MRP4, and P-gp. Km and Vmax were estimated as 3 µM and 3 
pmol/min/mg for pravastatin transport by BCRP. In the present study, only MRP3 
transported pravastatin. BCRP and MRP4 looked also promising transporters in the 
screening, but time-dependent experiments showed only weak if any transport. The Vmax 
and Km were estimated for MRP3, but the ATP-dependent transport did not reach plateau. 
Therefore, the results should be interpreted with caution. Pravastatin was a very 
challenging compound in the vesicle experiments from the start. Pravastatin is a relatively 
hydrophilic compound, indicating that diffusion in or out from vesicles cannot explain 
this. Variation between replicates was significant. This made the results unreliable and 
difficult to choose the transporters to the next phase from the screening and time-
dependent transport experiments. MRP3 was the only transporter, which indicated 
frequently signs of accumulation of pravastatin and was therefore the only transporter 
chosen into pravastatin concentration-dependent transport experiments.  
Previous reports have shown rosuvastatin to be substrate of BCRP (by using membrane 
vesicles) (Lee et al., 2019), MRP2 (Knauer et al., 2010), MRP3, MRP4 (by using 
membrane vesicles) (Kanda et el., 2018) and P-gp (Knauer et al., 2010). Transport studies 
of rosuvastatin by BCRP in membrane vesicles have resulted in Km and Vmax values of 2 
µM and 304 pmol/min/mg (Kitamura et al., 2008). MRP4-expressing membrane vesicles 
have yielded Km and Vmax values of 21 µM and 1140 pmol/min/mg (Pfeifer et al., 2013). 
Rosuvastatin is known to be a good substrate of BCRP, which was confirmed in the 
present study. This verifies the functionality of the used method and gives confidence 
also for the other findings. Concentration-depend transport of BCRP was investigated at 
lower concentration than other transporters, because of the known high affinity of 
rosuvastatin to BCRP. The calculated Km was 5 µM and Vmax was 88 pmol/min/mg for 
BCR. Km value is similar compared to study conducted by Kitamura et al (2008), but the 
Vmax value is lower. In the present study, P-gp also clearly transported rosuvastatin. 
MRP4 seemed to transport rosuvastatin in the screening and time-dependent transport 
experiment, but in the concentration-dependent transport experiments at higher 
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concentration rations, the accumulation dropped and kinetic parameters could therefore 
not be determined. 
Simvastatin is a difficult compound to study transport in vitro and there are only a few 
reports investigating the efflux transport of simvastatin. The parent simvastatin lactone 
are demonstrated not to be a substrate of BCRP, MRP2 nor P-gp in vitro (Li et al., 2011). 
However, in vivo studies have demonstrated simvastatin lactone to be substrate of BCRP 
and P-gp (Hsyu et al., 2001; Polli et al., 2013). In the present study, the transport of active 
simvastatin acid was investigated. In the screening experiments, no accumulation of 
simvastatin acid could be determined, but the results showed considerable variation. 
Simvastatin acid is a relatively lipophilic compound (Log D 1.5-1.75), which indicates 
that there may be significant diffusion of simvastatin acid into and out of the vesicles. 
More studies, potentially with different experimental systems are required to confirm 
whether simvastatin acid is a substrate of the studied efflux transporters.  
All of the statin and transporter combinations did not reach the point where ATP-
dependent transport plateaus. In cases of atorvastatin transport by BCRP and racemic 
fluvastatin transport by MRP2, reaching the plateau could have needed higher 
concentrations, or cannot be achieved with this method. On the contrary, atorvastatin 
transport by P-gp, racemic fluvastatin transport by MRP4, MRP8 and P-gp, pitavastatin 
transport by MRP3 and P-gp and rosuvastatin transport by MRP4 might have needed 
lower concentration points to achieve a better view of concentration-dependent transport 
and plateau of ATP-dependent transport. As a consequence, the calculated transport 
kinetic parameters for these statins and transporters should be interpreted with caution.  
Regarding individual transporters, BCRP transported rosuvastatin best of the studied 
statins in all the experiments. In addition, both fluvastatin enantiomers and racemic 
fluvastatin seemed to be substrates of BCRP. Atorvastatin and pitavastatin were well 
transported by BCRP, but to a smaller extent than rosuvastatin. The transport rates of 
MRP2 were very low for all the statins. MRP2 transported atorvastatin to the highest 
extent and signs of fluvastatin enantiomer transport were also observed, whereas 
pitavastatin, pravastatin and rosuvastatin did not differ from the control. In the previous 
literature, atorvastatin, fluvastatin, pravastatin and rosuvastatin have been shown to be 
substrates of MRP2 (Afrouzian et al., 2018; Knauer et al., 2010; Lin et al., 2001; Shin et 
al., 2017). In contrast, in the present study, none of these statins were well-transported by 
MRP2. This raises the question of whether the vesicles expressing MRP2 were somehow 
defective. It is possible that vesicles contain less protein than expected or contain wrongly 
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orientated transporters, which could alter the results. MRP2 protein quantification, 
determination of the membrane orientation of MRP2 in the vesicles and investigation of 
the transport of a prototype substrate would be required to verify the functionality of the 
used MRP2 vesicles.  
MRP3 was shown to transport atorvastatin, both fluvastatin enantiomers, racemic 
fluvastatin and pravastatin, but pitavastatin and rosuvastatin did not differ from control 
in the screening and time-dependent transport experiments., pravastatin was only 
transported by MRP3. Both fluvastatin enantiomers and rosuvastatin were well 
transported by MRP4 in the screening and time-dependent transport experiments, but 
transport was weak in the concentration-dependent transport experiments. Also variation 
in rosuvastatin transport was relatively high. Atorvastatin and pravastatin transport by 
MRP4 differed only slightly from the control and pitavastatin uptake did not ascend above 
the control levels. MRP8 showed transport of 3S,5R-fluvastatin and racemic fluvastatin. 
Pitavastatin also appeared to be transported by MRP8 in the screening, but in the time-
dependent transport experiment no pitavastatin transport by MRP8 could be observed. In 
the screening experiment, only pravastatin and rosuvastatin seemed not to be substrates 
of P-gp. However, in the time-dependent and concentration-dependent transport 
experiments, rosuvastatin was found to be transported by P-gp. Other experiments also 
revealed that racemic fluvastatin and pravastatin were not transported by P-gp.  
In conclusion, these data demonstrate that atorvastatin is a substrate of BCRP, MRP3 and 
P-gp, racemic fluvastatin is a substrate of BCRP, MRP2 and MRP3, pitavastatin is a 
substrate of BCRP, MRP3 and P-gp, pravastatin is a substrate of MRP3 and rosuvastatin 
is a substrate of BCRP and P-gp in vitro. The transport kinetic parameters Km and Vmax 
were successfully calculated for BCRP, MRP3- and P-gp-mediated transport of 
atorvastatin, BCRP-mediated transport of racemic fluvastatin, BCRP- and MRP3-
mediated transport of pitavastatin, and BCRP- and P-gp-mediated transport of 
rosuvastatin.  
This thesis improves general understanding of pharmacokinetic properties of atorvastatin, 
fluvastatin, pitavastatin, pravastatin and rosuvastatin. Efflux transporters play an 
important role in limiting the intestinal absorption and facilitating the excretion of statins 
and other drugs from the body. These data are useful in predicting the effects of 
transporter-mediated drug-drug interactions and genetic variability in transporter function 
on the pharmacokinetics, efficacy and safety of statin therapy.  
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4 MATERIALS AND METHODS 
4.1 Materials 
Vesicles were purchased as commercially available from Pharmtox, Radboud UMC, 
Nijmegen, the Netherlands. Assay buffer and stopping buffer were delivered included 
with the vesicles. All commercially purchased reagents and materials are shown in the 
table 12. For incubating plates in warm with mixing shake, ThermoMixer C (Eppendorf-
AG, Hamburg, Germany) and Thermo-Shaker PST-60HL (BioSan, Riga, Latvia) were 
used. Manifold 96-well Plate (Waters, Milford, Massachusetts, USA) were used to filtrate 
samples through the filtrate plates and in the end, samples were eluted by using Centrifuge 
5430 (Eppendorf, Hamburg, Germany). Storage plate containing samples were sealed 
with heat sealer model of 5390 000.034 (Eppendorf, Hamburg, Germany) and substrate 
concentrations were measured with liquid chromatography-tandem mass spectrometry. 
In the optimizing, the evaporation was conducted by using miVac DUO conctartor 
(Genevac, Ipsxich, UK) and CDCF fluorescence was measured with Cytation 5 (Biotek, 
Winooski, Vermont, U.S.A). pH balance of the solutions (washing buffer) was 
determined by using model 3510 pH meter (Jenway, Staffordshire, UK). 
Table12. Table of materials including catalogue number and supplier. 
Material Catalogue 
number of the 
supplier 
Supplier 
3R,5S-Fluvastatin  SC-206732 Santa Cruz 
Biotechnology (Dallas, 
Texas, USA) 
3S,5R-Fluvastatin SC-206738 Santa Cruz 
Biotechnology (Dallas, 
Texas, USA) 
96-well Clear Flat Bottom TC-
treated Microplate 
3585 Corning (Corning, New 
York, USA) 
96-well Clear Round Bottom 
Polypropylene Not Treated 
Microplate 




Atorvastatin Calcium salt A791750 Toronto research 
chemicals (Ontario, 
Canada) 





21882 Sigma-Aldrich (Saint 
Louis, Missouri, USA) 
DMSO D4540 Sigma-Aldrich (Saint 
Louis, Missouri, USA) 
Fluvastatin racemic SC-279169 Santa Cruz 
Biotechnology (Dallas, 
Texas, USA) 
Fluvastatin-D8  Toronto research 
chemicals (Ontario, 
Canada) 
FrameStar 96 Non-Skirted PCR 
plate 
4ti-0710/R 4titude (Wotton, UK) 
KCl (potassium chloride)  1.04936.0500 Merck (Darmstadt, 
Germany 
MeOH 34966 Honeywell (Charlotte, 
North-Carolina, USA) 
MgCl2 (magnesium chloride 
hexahydrate) 




M3183-100G Sigma-Aldrich (Saint 
Louis, Missouri, USA) 
MultiScreenHTS FB Filter Plate 1.0 
μm / 0.65 μm 
MSFBN6B50 Merck (Darmstadt, 
Germany 
Na2ATP A2383-5G Sigma-Aldrich (Saint 
Louis, Missouri, USA) 




Pitavastatin Calcium P531000 Toronto research 
chemicals (Ontario, 
Canada) 
Pitavastatin-D5 sodium salt P531007 Toronto research 
chemicals (Ontario, 
Canada) 
Pravastatin Sodium F702000 Toronto research 
chemicals (Ontario, 
Canada) 
Pravastatin-D9 sodium salt P702004 Toronto research 
chemicals (Ontario, 
Canada) 
Rosuvastatin Calcium salt R700500 Toronto research 
chemicals (Ontario, 
Canada) 
Rosuvastatin-D6  R700502 Toronto research 
chemicals (Ontario, 
Canada) 
Simvastatin acid  
 
 SynFine Research 
(Ontario, Canada) 





T-1378 Sigma-Aldrich (Saint 
Louis, Missouri, USA) 
 
4.2 Methods 
The vesicular transport assay was used to study the transport of statins by different efflux 
transporters. Vesicles were made from HEK293 cells transfected with efflux-transporter 
encoding baculovirus. Cells were single transfected, which enables overexpression and 
study of the specific transporter of interest.  
Vesicles were thawed on ice and the assays were performed on a 96-well round bottom 
plate. Vesicles were mixed with substrate solution (concentration of reagents: statins with 
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varying concentration, 100mM MgCl2, 1.5% DMSO and assay buffer provided with the 
vesicles). Substrate solution with vesicles, ATP and MQ-water were preincubated 
separately at 37°C with shaking for 10 min before the reaction. The active transport was 
initiated by adding ATP (final concentration of 4 mM) to the reaction mixture. In blank 
samples MQ-water was added instead of ATP. The reaction was performed at 37°C with 
shaking. Reaction time depended on the phase of the experiment (see below). Reaction 
was terminated by adding ice-cold stopping solution and samples were immediately 
transferred and filtered through 96-well filter plate. Vesicles, which were retained on the 
filter, were instantly washed again once with cold stopping solution and after terminating 
all the samples, again twice with stopping solution and twice with washing buffer (0.04M 
MOPS-Tris and 0.07M KCl). Filters were dried with dry filtration and lysis buffer was 
added to vesicles (25ng/ml internal standard and 50% MeOH). Lysis buffer was incubated 
for 10 min on ice to break the vesicles. Meanwhile, external standard of the statin was 
added to the filter plate during incubation. Lysis buffer and standards were eluted by 
centrifuging at 2204 g (+4500 rpm) for 10 minutes. Similarly, statin accumulation was 
investigated in control vesicles, which were control-transfected. Statin accumulation 
inside the vesicles were measured by liquid chromatography-tandem-mass spectrometry. 
 
Study was divided into optimizing and into three larger main phases: 
0) Optimizing vesicular transport assay:  
Before vesicular transport studies, the assay protocol was further optimized. Optimizing 
included 5 parts: 
i. Pre-wet of filter before sample transfer: To evaluate the effect of pre-wetting filter 
plate  before transferring the samples into filters, experiments were performed by 
transferring samples to dry filter plate after terminating the reaction and by 
transferring samples into the filter plate, which had been pre-wetted with MQ-water.  
ii. Evaporating of samples and dissolving into organic solvent: To improve signals, after 
performing the experiment, samples were evaporated at 37°C for 30 min and 25% 
acetonitrile was added.  
iii. Reduction of elution volume and eluting twice: To evaluate appropriate elution 
volume, same protocol was used with three statins (pitavastatin, pravastatin and 
rosuvastatin) and fluorescein substrate, CDCF. Several statins were used to study 
whether the effect varies between different statins. By using fluorescein substrate, it 
was possible to measure fluorescein right after experiment and pace up optimizing. 
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Elution was tested with volumes of 100µl and 50µl with statins, and volumes of 100 
µl, 75µl and 50µl with CDCF. CDCF was lysed with NaOH. To make sure all the 
statin is collected from the filters, the experiment was conducted with pravastatin and 
MRP3, and the filter plate was eluted twice by adding a second fresh eluant to filters 
and centrifuging. 
iv. Addition of vesicles into standards and pre-washing of filters before adding standard: 
To examine whether statins bind into vesicle matrix and affect measured signals, 
external standard was prepared both with and without vesicles. Impact of pre-washing 
to standard was studied by treating filter plate in two different ways before adding 
standard solutions: dry filters and filters treated three times with stopping buffer and 
twice with washing buffer.  
v. Termination of reaction with ice cold washing buffer: To evaluate effect of possible 
proteins in stopping buffer to mass spectrometric measurements, reaction was 
terminated with ice cold washing buffer and only washed with washing buffer. 
 
1) Screening of statin transport: 
Which transporters transport each statin was studied in the screening. BCRP, P-gp, 
MRP2, MRP3, MRP4 and MRP8 transporters were studied as potential transporters for 
all the statins of interest (atorvastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin 
and simvastatin acid). Screening was performed with two concentrations (1 µM and 10 
µM), which gave a general insight of transport for further studies and reaction incubation 
time was 10 minutes. Based on these results, it was evaluated which transporters show 
active transport for each statin. Transporters and statin concentration for the further parts 
of the study were selected based on the screening results. 
2) Determination of time-dependent transport: 
In the transport-time linearity studies, the optimum reaction incubation time was 
examined more specifically. The experiment was performed by using one statin 
concentration and incubation times were 5, 10 and 15 minutes, aiming to see the time 
linearity in the statin transport. Based on these results, the incubation time for the 





3) Determination of concentration-dependent transport: 
In the final kinetic studies, several statin concentrations were examined, with the 
incubation time selected based on time-linearity studies. The aim was to determine 
concentration-dependent accumulation of statins. The results were used to determine 
kinetic parameters of the active transport for each statin. 
4.3 Data analysis 
ATP-dependent transport was determined by calculating the difference between the statin 
accumulation inside the vesicles in the presence and absence of ATP (Equation 1). By 
dividing ATP-dependent transport with incubating time and transporter protein 
abundance, ATP-dependent transport obtains the form pmol/min/mg. Standard deviation 
(SD) for ATP-dependent transport was determined by summing second power of statin 
accumulation SD in presence and absence of ATP and dividing with two (Equation 2). 
The ratio for statin transport was calculated by dividing accumulated statin (pmol) in 
presence of ATP with the amount accumulated in absence of ATP (Equation 3). The SD 
for ratio is calculated with the equation [(SD1/T1)^2+(SD2/T2)^2] x 0.5 x Ratio 
(Equation 4). In equations 2, 3 and 4, T1 is statin transport in the presence of ATP and 
T2 in the absence on ATP, SD1 is the deviation for accumulation in presence of ATP and 
SD2 in the absence of ATP. The kinetic parameters of substrate transport were calculated 
by curve fitting using the Michaelis-Menten equation, by GraphPad Prism version 8.1.2 
(GraphPad Software Inc., La Jolla, CA).  Michaelis-Menten equation is V=Vmax [S]/([S] 
+ Km ), where V is the velocity of ATP-dependent transport, Vmax  is maximal velocity, 
[S] is substrate concentration (µM) (statin concentration in the study), and Km is the 
Michaelis-Menten constant (Equation 5). In addition, GraphPad Prism was used to draw 
all the figures.  
ATP-dependent transport = Transport+ATP – Transport-ATP         (Eq.1) 
𝑆𝐷 𝑜𝑓 𝐴𝑇𝑃 − 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 𝑡𝑟𝑎𝑛𝑠𝑝𝑜𝑟𝑡 =  
(𝑆𝐷1 )2+(𝑆𝐷2)2
2
    (Eq.2) 
𝑅𝑎𝑡𝑖𝑜 =  
𝑇1 
𝑇2
        (Eq.3) 
𝑆𝐷 𝑜𝑓 𝑟𝑎𝑡𝑖𝑜 =  
(𝑆𝐷1/𝑇1)2+(𝑆𝐷2/𝑇2)2
2
∗ 𝑅𝑎𝑡𝑖𝑜  (Eq.4) 
𝑣 =  
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +[𝑆]
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ABC ATP-binding cassette 
ATP Adenosine triphosphate 
BCRP Breast cancer resistance protein 
CDCF 5(6)-carboxy-2,'7'-dichlorofluorescein 
CYP Cytochrome P450 
HMG-CoA 3-hydroxy-3-methylglutary-coenzyme A 
LDL Low-density lipoprotein 
MRP Multidrug-resistance associated protein 
NBD Nucleotide-binding domain 
OATP Organic anion transporting polypeptides 
P-gp P-glycoprotein 
SD Standard deviation  
SLC Solute carrier 
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S. Ōmura, S. Sahlin, B. Angelin, L.L. Rudel, and M. Eriksson. 2008. Cholesterol Synthesis Inhibition 
Elicits an Integrated Molecular Response in Human Livers Including Decreased 
ACAT2. Arterioscler.Thromb.Vasc.Biol. 28. doi: 10.1161/ATVBAHA.107.157172. 
Parker, T.S., D.J. McNamara, C.D. Brown, R. Kolb, E.H. Ahrens, A.W. Alberts, J. Tobert, J. Chen, 
and P.J. De Schepper. 1984. Plasma mevalonate as a measure of cholesterol synthesis in 
man. J.Clin.Invest. 74:795-804. doi: 10.1172/JCI111495. 
Pasanen, M.K., Neuvonen, M., Neuvonen, P.J. and Niemi, M. 2006. SLCO1B1 polymorphism 
markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics.16:873-9. doi: 
10.1097/01.fpc.0000230416.82349.90. PMID: 17108811. 
Pasternak, R.C., S.C. Smith, C. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant. 2002. 
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 33:2337-2341. doi: 
10.1161/01.str.0000034125.94759.41. 
Patti, G., M. Chello, D. Candura, V. Pasceri, A. D’Ambrosio, E. Covino, and G. Di Sciascio. 2006. 
Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients 
Undergoing Cardiac Surgery. Circulation. 114. doi: 10.1161/CIRCULATIONAHA.106.621763. 
Pfeifer, N.D., K. Yang, and K.L.R. Brouwer. 2013. Hepatic Basolateral Efflux Contributes 
Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance 
Using a Novel Protocol in Sandwich-Cultured Hepatocytes. Journal of Pharmacology and 
Experimental Therapeutics. 347. doi:10.1124/jpet.113.207472. 
Pichard, L., I. Fabre, G. Fabre, J. Domergue, B. Saint Aubert, G. Mourad, and P. Maurel. 1990. 
Screening for Inducers and Inhibitors of Cytochrome P-450 (Cyclosporin A Oxidase) in Primary 
Cultures of Human Hepatocytes and in Liver Microsomes. 18. 
66 
 
Polli, J.W., E. Hussey, M. Bush, G. Generaux, G. Smith, D. Collins, S. McMullen, N. Turner, and D.J. 
Nunez. 2013. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from 
in vitro data to clinical study design. Xenobiotica. 43. doi:10.3109/00498254.2012.739719. 
Polli, J.W., K.L. Olson, J.P. Chism, L. John-Williams, R.L. Yeager, S.M. Woodard, V. Otto, S. 
Castellino, and V.E. Demby. 2009. An Unexpected Synergist Role of P-Glycoprotein and Breast 
Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor 
Lapatinib ( N -{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-
(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016): TABLE 1. Drug 
Metab.Disposition. 37. doi: 10.1124/dmd.108.024646. 
Prueksaritanont, T., B. Ma, and N. Yu. 2003. The human hepatic metabolism of simvastatin hydroxy 
acid is mediated primarily by CYP3A, and not CYP2D6. Br.J.Clin.Pharmacol. 56:120-124. 
Prueksaritanont, T., B. Ma, X. Fang, R. Subramanian, J. Yu, and J.H. Lin. 2001. Oxidation of 
simvastatin in mouse liver preparations. 
Prueksaritanont, T., R. Subramanian, X. Fang, B. Ma, Y. Qiu, J.H. Lin, P.G. Pearson, and T.A. Baillie. 
2002. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. 
Prueksaritanont, T., Tatosian, D.A., Chu, X., Railkar, R., Evers, R., Chavez-Eng, C., Lutz, R., Zeng, 
W., Yabut, J., Chan, G.H., Cai, X., Latham, A.H., Hehman, J., Stypinski, D., Brejda, J., Zhou, C., 
Thornton, B., Bateman, K.P., Fraser, I. and Stoch, S.A.. 2017. Validation of a Microdose probe drug 
cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol 
Ther. 101:519-530. doi:10.1002/cpt.525. Epub 2016 Dec 10. PMID: 27943276. 
Raab, M., S. Kappel, A. Krämer, M. Sanhaji, Y. Matthess, E. Kurunci-Csacsko, J. Calzada-Wack, B. 
Rathkolb, J. Rozman, T. Adler, D.H. Busch, I. Esposito, H. Fuchs, V. Gailus-Durner, M. Klingenspor, 
E. Wolf, N. Sänger, F. Prinz, M.H.d. Angelis, J. Seibler, J. Yuan, M. Bergmann, R. Knecht, B. Kreft, 
and K. Strebhardt. 2011. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice 
and cultured primary mammalian cells. Nature Communications. 2. doi: 10.1038/ncomms1395. 
Radomski, M.W., R.M.J. Palmer, and S. Moncada. 1987. The anti-aggregating properties of vascular 
endothelium: interactions between prostacyclin and nitric oxide. Br.J.Pharmacol. 92. doi: 
10.1111/j.1476-5381.1987.tb11367.x. 
Reddy, K.G., R.N. Nair, H.M. Sheehan, and J.M. Hodgson. 1994. Evidence that selective endothelial 
dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with 
risk factors for atherosclerosis. J.Am.Coll.Cardiol. 23. doi: 10.1016/0735-1097(94)90627-0. 
Reid, G., P. Wielinga, N. Zelcer, I. van der Heijden, A. Kuil, M. de Haas, J. Wijnholds, and P. Borst. 
2003. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter 
and is inhibited by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of 
Sciences. 100. doi: 10.1073/pnas.1033060100. 
Rius, M., A.T. Nies, J. Hummel-Eisenbeiss, G. Jedlitscgky, and D. Keppler. 2003. Cotransport of 
reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte 
membrane. Hepatology. 38. doi: 10.1053/jhep.2003.50331. 
Rosenson, R.S. 2003. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of 
dyslipidemia. Expert Review of Cardiovascular Therapy. 1. doi:10.1586/14779072.1.4.495. 
Roth, G.A., M.H. Forouzanfar, A.E. Moran, R. Barber, G. Nguyen, V.L. Feigin, M. Naghavi, G.A. 
Mensah, and C.J.L. Murray. 2015. Demographic and Epidemiologic Drivers of Global Cardiovascular 
Mortality. N.Engl.J.Med. 372. doi: 10.1056/NEJMoa1406656. 
Sacks, F.M., M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. 
Warnica, J.M. Arnold, C. Wun, B.R. Davis, and E. Braunwald. 1996. The Effect of Pravastatin on 
Coronary Events after Myocardial Infarction in Patients with Average Cholesterol 
Levels. N.Engl.J.Med. 335:1001-1009. doi: 10.1056/NEJM199610033351401. 
67 
 
Saito, H., H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. 
Konomi, E. Tao, N. Tsujikawa, S. Tarui, M. Nagakura, M. Osumi, and T. Ishikawa. 2006. A New 
Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to 
Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug 
Interactions. J.Pharmacol.Exp.Ther. 317. doi: 10.1124/jpet.105.099036. 
Sandusky, G.E., K.S. Mintze, S.E. Pratt, and A.H. Dantzig. 2002. Expression of multidrug resistance-
associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. :65-
74. 
Sattar, N., D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A. de Craen J.M., S.R.K. Seshasai, J.J. 
McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, 
J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. 
Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. 
Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford. 2010. Statins and risk of incident diabetes: 
a collaborative meta-analysis of randomised statin trials. The Lancet. 375. doi: 10.1016/S0140-
6736(09)61965-6. 
Scandinavian Simvastatin Survival Study, G. 1994. Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The 
Lancet. 344:1383-1389. doi: 10.1016/S0140-6736(94)90566-5. 
Schaub, T.P., J.¨. Urgen Kartenbeck, Org K ¨ Onig, J ¨, H. Spring, J.D.¨. Orsam, G. Staehler, S. 
St¨orkel, S. St¨orkel, W.F. Thon, and D. Keppler. 1999. Expression of the MRP2 Gene-Encoded 
Conjugate Export Pump in Human Kidney Proximal Tubules and in Renal Cell Carcinoma. 
Scheffer, G.L., M. Kool, M. De Haas, J. Marleen, L. De Vree, Pijnenborg, Adriana C. L. M., D.K. 
Bosman, Elferink, Ronald P. J. Oude, P. Van Der Valk, P. Borst, and R.J. Scheper. 2002. Tissue 
Distribution and Induction of Human Multidrug Resistant Protein 3. 
Scripture, C.D., and J.A. Pieper. 2001. Clinical Pharmacokinetics of Fluvastatin. Clinical 
Pharmacokinetics. 40. doi:10.2165/00003088-200140040-00003. 
SEARCH Collaborative Group, Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, 
F., Gut, I., Lathrop, M. and Collins, R. 2008. SLCO1B1 variants and statin-induced myopathy--a 
genomewide study. N Engl J Med. 359:789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23. 
PMID: 18650507. 
Seithel, A., S. Eberl, K. Singer, D. Auge, G. Heinkele, N.B. Wolf, F. Dörje, M.F. Fromm, and J. König. 
2007. The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated 
by OATP1B1 and OATP1B3. Drug Metabolism and Disposition. 35. doi:10.1124/dmd.106.014407 
Senthilkumari, S., T. Velpandian, N.R. Biswas, A. Bhatnagar, G. Mittal, and S. Ghose. 2009. 
Evidencing the Modulation of P-glycoprotein at Blood-Ocular Barriers using Gamma 
Scintigraphy. Curr.Eye Res. 34. doi: 10.1080/02713680802563430. 
Serizawa, N., and T. Matsuoka. 1991. A two component-type cytochrome P-450 monooxygenase 
system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective 
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochimica Et Biophysica Acta (BBA) 
- Lipids and Lipid Metabolism. 1084. doi: 10.1016/0005-2760(91)90052-J. 
Sharma, P., C.J. Butters, V. Smith, R. Elsby, and D. Surry. 2012. Prediction of the in vivo OATP1B1-
mediated drug–drug interaction potential of an investigational drug against a range of 
statins. European Journal of Pharmaceutical Sciences. 47. doi: 10.1016/j.ejps.2012.04.003. 
Sharom, F.J. 2014. Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the 




Sharom, F.J., P. Lu, R. Liu, and X. Yu. 1998. Linear and cyclic peptides as substrates and modulators 
of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochemical 
Journal. 333. doi:10.1042/bj3330621. 
Shawahna, R., Y. Uchida, X. Declèves, S. Ohtsuki, S. Yousif, S. Dauchy, A. Jacob, F. Chassoux, C. 
Daumas-Duport, P. Couraud, T. Terasaki, and J. Scherrmann. 2011. Transcriptomic and Quantitative 
Proteomic Analysis of Transporters and Drug Metabolizing Enzymes in Freshly Isolated Human Brain 
Microvessels. Molecular Pharmaceutics. 8. doi: 10.1021/mp200129p. 
Shin, E., N. Shin, J.H. Oh, and Y.J. Lee. 2017. High-Dose Metformin May Increase the Concentration 
of Atorvastatin in the Liver by Inhibition of Multidrug Resistance–Associated Protein 
2. J.Pharm.Sci. 106:961-967. doi: 10.1016/j.xphs.2016.11.020. 
Siedlik, P.H., S.C. Olson, B.B. Yang, and R.H. Stern. 1999. Erythromycin coadministration increases 
plasma atorvastatin concentrations. J.Clin.Pharmacol. 39:501-4. doi: 10.1177/009127009903900510. 
Silva, M., M.L. Matthews, C. Jarvis, N.M. Nolan, P. Belliveau, M. Malloy, and P. Gandhi. 2007. 
Meta-analysis of drug-induced adverse events associated with intensive-dose statin 
therapy. Clin.Ther. 29. doi: 10.1016/j.clinthera.2007.02.008. 
Singh, R.K., A.S. Haka, A. Brumfield, I. Grosheva, P. Bhardwaj, H.F. Chin, Y. Xiong, T. Hla, and 
F.R. Maxfield. 2017. Ceramide activation of RhoA/Rho kinase impairs actin polymerization during 
aggregated LDL catabolism. J.Lipid Res. 58. doi: 10.1194/jlr.M076398. 
Singhvi, S.M., H.Y. Pan, R.A. Morrison, and D.A. Willard. 1990. Disposition of pravastatin sodium, 
a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br.J.Clin.Pharmacol. 29. doi: 
10.1111/j.1365-2125.1990.tb03626.x. 
Soroka, C.J., J.M. Lee, F. Azzaroli, and J.L. Boyer. 2001. Cellular localization and up-regulation of 
multidrug resistance–associated protein 3 in hepatocytes and cholangiocytes during obstructive 
cholestasis in rat liver. Hepatology. 33:783-791. doi: 10.1053/jhep.2001.23501. 
Soyseth, V., P.H. Brekke, P. Smith, and T. Omland. 2006. Statin use is associated with reduced 
mortality in COPD. European Respiratory Journal. 29. doi: 10.1183/09031936.00106406. 
Sparreboom, A., J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K.F. Meijer, P. Borst, W.J. 
Nooijen, J.H. Beijnen, and O. van Tellingen. 1997. Limited oral bioavailability and active epithelial 
excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National 
Academy of Sciences. 94. doi: 10.1073/pnas.94.5.2031. 
Srikanthan, P., A.L. Hevener, and A.S. Karlamangla. 2010. Sarcopenia Exacerbates Obesity-
Associated Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition 
Examination Survey III. PLoS ONE. 5. doi: 10.1371/journal.pone.0010805. 
Srinivas, R.V., D. Middlemas, P. Flynn, and A. Fridland. 1998. Human Immunodeficiency Virus 
Protease Inhibitors Serve as Substrates for Multidrug Transporter Proteins MDR1 and MRP1 but 
Retain Antiviral Efficacy in Cell Lines Expressing These Transporters. Antimicrob.Agents 
Chemother. 42. doi: 10.1128/AAC.42.12.3157. 
Stienstra, R., Y. Haim, Y. Riahi, M. Netea, A. Rudich, and G. Leibowitz. 2014. Autophagy in adipose 
tissue and the beta cell: implications for obesity and diabetes. Diabetologia. 57. doi:10.1007/s00125-
014-3255-3. 
Stern, R.H., B.-. Yang, M. Horton, S. Moore, R.B. Abel, and S.C. Olson. 1997. Renal Dysfunction 
Does Not Alter the Pharmacokinetics or LDL-Cholesterol Reduction of Atorvastatin. The Journal of 
Clinical Pharmacology. 37. doi: 10.1002/j.1552-4604.1997.tb05629.x. 
St-pierre, M., M.A. Serrano, R.I. R Macias, U. Dubs, M. Hoechli, U. Lauper, P.J. Meier, and J.J. G 




Suzuki, M., H. Iwasaki, Y. Fujikawa, M. Kitahara, M. Sakashita, and R. Sakoda. 2001. Synthesis and 
biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorganic & Medicinal 
Chemistry. 9. doi:10.1016/S0968-0896(01)00198-5. 
Suzuki, M., H. Suzuki, Y. Sugimoto, and Y. Sugiyama. 2003. ABCG2 Transports Sulfated Conjugates 
of Steroids and Xenobiotics. J.Biol.Chem. 278:22644-22649. doi: 10.1074/jbc.M212399200. 
Tamai, O., H. Matsuoka, H. Itabe, Y. Wada, K. Kohno, and T. Imaizumi. 1997. Single LDL Apheresis 
Improves Endothelium-Dependent Vasodilatation in Hypercholesterolemic 
Humans. Circulation. 95:76-82. doi: 10.1161/01.CIR.95.1.76. 
Tammur, J., C. Prades, I. Arnould, A. Rzhetsky, A. Hutchinson, M. Adachi, J.D. Schuetz, K.J. 
Swoboda, L.J. Ptácek, M. Rosier, M. Dean, and R. Allikmets. 2001. Two new genes from the human 
ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on 
chromosome 16q12. Gene. 273. doi:10.1016/S0378-1119(01)00572-8 
Tanner, F.C., G. Noll, C.M. Boulanger, and T.F. Lüscher. 1991. Oxidized low density lipoproteins 
inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived 
nitric oxide. Circulation. 83. doi: 10.1161/01.CIR.83.6.2012. 
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. 1984. The relationship of 
reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Assoc. 251: 365–
374. 
Thiebaut, F., T. Tsuruot, H. Hamadat, M.M. Gottesman, I. Pastan, and M.C. Willingham. 1987. 
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues 
(immunohistochenistry/liver/adrenal/kidney/cancer 
chemotherapy). Proc.Nati.Acad.Sci.USA. 84:7735-7738. 
Thomas, J., L. Wang, R.E. Clark, and M. Pirmohamed. 2004. Active transport of imatinib into and out 
of cells: implications for drug resistance. Blood. 104. doi: 10.1182/blood-2003-12-4276. 
Tobert, J.A. 1988. Efficacy and long-term adverse effect pattern of lovastatin. The American Journal 
of Cardiology. 62. doi:10.1016/0002-9149(88)90004-5. 
Todd, P.A., and K.L. Goa. 1990. Simvastatin. Drugs. 40. doi:10.2165/00003495-199040040-00007. 
Tomlinson, B., and M. Hu. 2013. Current perspectives on rosuvastatin. Integrated Blood Pressure 
Control. 6:15–25. doi:10.2147/IBPC.S34814. 
Treasure, C.B., J.L. Klein, W.S. Weintraub, J.D. Talley, M.E. Stillabower, A.S. Kosinski, J. Zhang, 
S.J. Boccuzzi, J.C. Cedarholm, and R.W. Alexander. 1995. Beneficial Effects of Cholesterol-
Lowering Therapy on the Coronary Endothelium in Patients with Coronary Artery 
Disease. N.Engl.J.Med. 332:481-487. doi: 10.1056/NEJM199502233320801. 
Triscari, J., D. O'Donnell, M. Zinny, and H.Y. Pan. 1995. Gastrointestinal Absorption of Pravastatin 
in Healthy Subjects. The Journal of Clinical Pharmacology. 35. doi: 10.1002/j.1552-
4604.1995.tb05002.x. 
Tse, F.L.S., D.F. Nickerson, and W.S. Yardley. 1993. Binding of Fluvastatin to Blood Cells and 
Plasma Proteins. J.Pharm.Sci. 82. doi: 10.1002/jps.2600820914. 
Tse, F.L.S., J.M. Jaffe, and A. Troendle. 1992. Pharmacokinetics of Fluvastatin After Single and 
Multiple Doses in Normal Volunteers. The Journal of Clinical Pharmacology. 32. doi: 
10.1002/j.1552-4604.1992.tb05773.x. 
Tubic-Grozdanis, M., J.M. Hilfinger, G.L. Amidon, J.S. Kim, P. Kijek, P. Staubach, and P. Langguth. 
2008. Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed 
Versus Immediate Release Oral Dosage Forms. Pharm.Res. 25. doi: 10.1007/s11095-007-9519-6. 
70 
 
Tuccori, M., F. Lapi, A. Testi, D. Coli, U. Moretti, A. Vannacci, D. Motola, F. Salvo, A.L. Rivolta, 
C. Blandizzi, A. Mugelli, and M. Del Tacca. 2008. Statin-Associated Psychiatric Adverse 
Events. Drug Safety. 31. doi: 10.2165/0002018-200831120-00007. 
Uchida, Y., S. Ohtsuki, Y. Katsukura, C. Ikeda, T. Suzuki, J. Kamiie, and T. Terasaki. 2011. 
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and 
receptors. J.Neurochem. 117. doi: 10.1111/j.1471-4159.2011.07208.x. 
Uedas, K., N. Okamuraj, M. Hiraij, Y. Tanigawaraj, T. Saeki, N. Kioka, T. Komano, and R. Horij. 
1992. Human P-glycoprotein Transports Cortisol, Aldosterone, and Dexamethasone, but Not 
Progesterone*. 267:24248-24252. 
Vallance, P., J. Collier, and S. Moncada. 1989. Effects of endothelium-derived oxide on peripheral 
arteriolar tone in man. The Lancet. 334. doi: 10.1016/S0140-6736(89)91013-1. 
Van Aubel, Rémon A. M. H., P.H.E. Smeets, J.G.P. Peters, R.J.M. Bindels, and F.G.M. Russel. 2002. 
The MRP4/ABCC4 Gene Encodes a Novel Apical Organic Anion Transporter in Human Kidney 
Proximal Tubules: Putative Efflux Pump for Urinary cAMP and cGMP. 
Van Endert, P.M. 1999. Role of Nucleotides and Peptide Substrate for Stability and Functional State 
of the Human ABC Family Transporters Associated with Antigen Processing. J.Biol.Chem. 274. doi: 
10.1074/jbc.274.21.14632. 
Vasiliou, V., K. Vasiliou, and D.W. Nebert. 2008. Human ATP-binding cassette (ABC) transporter 
family. Human Genomics. 3:281–290. doi:10.1186/1479-7364-3-3-281. 
vegy, C., T. Litman, G. Szakács, Z. Nagy, S. Bates, A. Váradi, and B. Sarkadi. 2001. Functional 
Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect 
Cells. Biochem.Biophys.Res.Commun. 285. doi: 10.1006/bbrc.2001.5130. 
Verhalen, B., and S. Wilkens. 2011. P-glycoprotein Retains Drug-stimulated ATPase Activity upon 
Covalent Linkage of the Two Nucleotide Binding Domains at Their C-terminal 
Ends. J.Biol.Chem. 286. doi: 10.1074/jbc.M110.193151. 
Vickers, S., C.A. Duncan, I.-. Chen, A. Rosegay, and D.E. Duggan. 1990b. Metabolic disposition 
studies on simvastatin, a cholesterol-lowering prodrug. 18. 
Vickers, S., C.A. Duncan, K.P. Was, P.H. Karl, B. Arison, S.A. Prakash, H.0. Ramjit, S.M. 
Pitzenberger, G. Stokker, and D.E. Duggan. 1990a. Lactone form (SV) IN WTRO AND IN WVO 
BIOTRANSFORMATION OF SIMVASTATIN, AN INHIBITOR OF HMG CoA REDUCTASE. 18. 
Vildhede, A., A. Mateus, E.K. Khan, Y. Lai, M. Karlgren, P. Artursson, and M.C. Kjellsson. 2016. 
Mechanistic modeling of pitavastatin disposition in sandwich-cultured human hepatocytes: A 
proteomics-informed bottom-up approach. Drug Metabolism and Disposition. 44:505–516. 
doi:10.1124/dmd.115.066746. 
Virgintino, D., D. Robertson, M. Errede, V. Benagiano, F. Girolamo, E. Maiorano, L. Roncali, and M. 
Bertossi. 2002. Expression of P-Glycoprotein in Human Cerebral Cortex Microvessels. The Journal 
of Histochemistry & Cytochemistry. 50:1671-1676. 
Vlaming, M.L.H., K. Mohrmann, E. Wagenaar, D.R. de Waart, R.P.J.O. Elferink, J.S. Lagas, O. van 
Tellingen, L.D. Vainchtein, H. Rosing, J.H. Beijnen, J.H.M. Schellens, and A.H. Schinkel. 2006. 
Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 ( Abcc2 ) Knockout 
Mice. Journal of Pharmacology and Experimental Therapeutics. 318. doi:10.1124/jpet.106.101774. 
Ward, A.B., P. Szewczyk, V. Grimard, C.-. Lee, L. Martinez, R. Doshi, A. Caya, M. Villaluz, E. 
Pardon, C. Cregger, D.J. Swartz, P.G. Falson, I.L. Urbatsch, C. Govaerts, J. Steyaert, and G. Chang. 
2013. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the 




Wassmann, S., U. Laufs, A.T. Bäumer, K. Müller, K. Ahlbory, W. Linz, G. Itter, R. Rösen, M. Böhm, 
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